214455ec的个人主页 - 老虎社区

214455ec

暂无个人介绍

IP属地：未知

1关注

0粉丝

0主题

0勋章

2021-12-30

Good to know

3 Unstoppable Stocks That Could Create Lasting Generational Wealth

2021-12-28

Thanks

S&P 500 closes at record high on retail sales cheer

2021-12-27

Thanks

S&P 5,000? Here's What Analysts And Investors Expect From The Stock Market In 2022

2021-12-26

Like

7 Reasons the Stock Market Could Crash in January

2021-12-25

Thanks

3 Charts to Consider if You Want to Own an EV Stock

2021-12-24

It's going to be another bumper year for Pfizer

抱歉，原内容已删除

2021-12-23

This will help the economy to avoid lock downs

U.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use

2021-12-23

This will be interesting since she's fighting the dominant power of Big Tech

抱歉，原内容已删除

2021-12-21

BB in play to buy stocks cheap again

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":4094037277039370,"uuid":"4094037277039370","gmtCreate":1630991705421,"gmtModify":1639708481500,"name":"214455ec","pinyin":"blessedone55","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":1,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.61%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":692909153,"gmtCreate":1640819766981,"gmtModify":1640819766981,"author":{"id":"4094037277039370","authorId":"4094037277039370","name":"214455ec","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"Good to know","listText":"Good to know","text":"Good to know","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/692909153","repostId":"2195345230","repostType":4,"repost":{"id":"2195345230","pubTimestamp":1640790918,"share":"https://www.laohu8.com/m/news/2195345230?lang=&edition=full","pubTime":"2021-12-29 23:15","market":"us","language":"en","title":"3 Unstoppable Stocks That Could Create Lasting Generational Wealth","url":"https://stock-news.laohu8.com/highlight/detail?id=2195345230","media":"Motley Fool","summary":"If you want to leave some stocks to your heirs, then you'll want to find companies like these that are poised to thrive for decades to come.","content":"<html><head></head><body><p>Building generational wealth doesn&#39;t happen very often. Only 27% of people whose parents have college degrees have received an inheritance of any kind in 2019, according to the Federal Reserve&#39;s Survey of Consumer Finances. If your parents didn&#39;t go to college, your odds are slightly worse. And the median inheritance received from college-degree parents was only $92,700. That amount is nothing to sneeze at, but there&#39;s taxes to think about. Moreover, this is the <i>median</i> inheritance. By definition, half of the people who did receive an inheritance received less than this.</p><p>The point is, the vast majority of us haven&#39;t and probably won&#39;t be receiving generational wealth from our parents. And this reality from the past can&#39;t be changed. But we can do something about the future by building wealth to pass on to the next generation by saving and investing our own incomes now.</p><p>Of course, if you&#39;re looking for stocks you can buy, hold, and pass on to your heirs, then you need to find companies that are unstoppable. For me, <b>Unity Software</b> (NYSE:U), <b>Axon Enterprise</b> (NASDAQ:AXON), and <b>Lam Research</b> (NASDAQ:LRCX) are three companies that might fit this description. These aren&#39;t necessarily three stocks with the highest upside. Indeed, they might struggle to beat the market average some years. But I do expect them to have greater longevity than many other stock options, so they&#39;re perfect for building generational wealth.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d959f34eea882801d52573e855175e8b\" tg-width=\"700\" tg-height=\"393\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><h2>Unity: The preferred platform to build the future</h2><p>Unity offers easy-to-use software for creating three-dimensional (3D) content and developing ways for users to interact with these 3D images. Think broadly. This software has applications in gaming, animation, augmented reality, the metaverse, and more. And according to the company, over half of all 3D content built today is built using Unity.</p><p>There&#39;s good reason to believe that Unity can keep its leadership position in the 3D space. Consider that the company doesn&#39;t charge people for its software if they&#39;re students or if their companies generate less than $100,000 in annual revenue. In other words, anyone new to the 3D game is very likely to choose Unity because it&#39;s the industry standard and -- more persuasively -- it&#39;s <i>free</i>. And once they create a viable business with over $100,000 in revenue, Unity can then start to profit as well.</p><p>This kind of value proposition for new creators is going to make Unity hard to stop. Furthermore, consider something interesting with the company&#39;s business model: You can create mobile games, for example, with Unity. And creating things is recorded in the company&#39;s Create Solutions segment, a subscription-revenue product. But once games are created, you can also use Unity to operate them and get them monetized, etc. This revenue is recorded in its Operate Solutions segment, and it&#39;s not a straight subscription but rather a usage-based revenue model, meaning Unity makes more money as their customers succeed.</p><p>Unity is likely to attract a lot of creators because of its value proposition. These can then stick with Unity to operate their digital content. And assuming Unity does a good job here, its revenue has uncapped upside because it&#39;s a usage-based revenue model. In the third quarter of 2021, Unity had a net-dollar expansion rate of 142%, which clearly demonstrates its customers are spending more money over time and its business model is working.</p><p>According to Unity&#39;s management, only around 2% of the world&#39;s digital content is currently made in 3D. It&#39;s only reasonable to assume that this will increase substantially in coming years. I&#39;ll refrain from giving a set-in-stone forecast. But if 3D content had 5% to 10% share, it would still be a relatively small part of the overall market. And in this scenario, Unity could more than double its business just by maintaining its leadership position in the space.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/27ffa2b7d04e8a286c29ab0b6152e284\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Axon Enterprise.</span></p><h2>Axon: Making work easy and switching hard</h2><p>If Axon Enterprise only offered Tasers to police departments, then this would be a fragile business. But its decision to offer software solutions in conjunction with its hardware devices has made this an unstoppable business in my opinion. Here&#39;s why.</p><p>Axon&#39;s Tasers are infrequent purchases with little recurring-revenue potential. But they do enjoy widespread adoption. In the U.S., 21% of law enforcement, federal, and corrections agencies, along with enterprises, are already Taser users, according to the company.</p><p>Brilliantly, Axon leveraged its existing customer relationships into streams of recurring revenue when it decided to develop software solutions. Law enforcement officers can now automatically have evidence backed up to the cloud. And artificial-intelligence (AI) software can quickly fill out tedious paperwork. It&#39;s apparent its customers appreciate these software solutions because they&#39;re increasing spending, as measured by its 119% net-dollar retention rate in the third quarter of 2021. Moreover, Axon&#39;s hardware and software is increasingly a package deal. According to the company, 73% of total revenue in 2020 was tied to a subscription product.</p><p>Axon Cloud is the fastest growing part of Axon&#39;s business these days. In Q3, software-as-a-service (SaaS) revenue was up almost 42% year over year compared to total revenue growth of just 39%. And management estimates its cloud-solutions product is still only 2% penetrated in the U.S. compared to the aforementioned 21% market penetration for Taser. This means Axon has a robust growth opportunity ahead just within its existing customer base, to say nothing of new customers.</p><p>Once data is stored on the cloud, it&#39;s extremely inconvenient for customers to switch. This is the main reason I believe Axon is unstoppable. But the company also seems poised for more growth considering there&#39;s few companies -- if any -- that offer the broad suite of products that Axon does. The possibility of strong future growth was confirmed in Q3 with bookings. These represent spending commitments that can&#39;t be counted as revenue yet but are very likely to come in during future quarters. In Q3, Axon had bookings of $488 million, which was a quarterly record.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ca0886affdbc066a045e7c4d5f02ec3c\" tg-width=\"700\" tg-height=\"465\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><h2>Lam Research: Good luck trying to disrupt this <a href=\"https://laohu8.com/S/AONE.U\">one</a></h2><p>Have you ever noticed how many carbonated beverage companies there are? One reason why there are so many is because it&#39;s relatively easy to create, package, and sell a drink. There&#39;s a low &#34;barrier to entry.&#34; However, when it comes to creating equipment to manufacture semiconductor products, the barrier to entry couldn&#39;t be higher, which is why Lam Research is unstoppable. It faces little risk of being disrupted by a newcomer anytime soon.</p><p>Lam Research is a diversified business. That said, 64% of revenue comes from systems used for making memory products. Therefore, it&#39;s important to watch that segment of the industry. And in the near term, things are looking bright. Consider the outlook from memory company <b>Micron Technology</b>, which is a major industry player. Management from Micron just said it expects demand in 2022 to increase over 30% for NAND memory (flash memory) and over 20% for DRAM memory (dynamic random access memory) products. This suggests that Lam Research&#39;s services will be in hot demand in the coming year.</p><p>Beyond 2022, things also look bright for Lam Research. Various third-party market research reports confirm the general upward trend of the semiconductor industry. One example comes from Precedence Research, which predicts the entire industry will grow at an almost 7% compound annual growth rate (CAGR) through 2030, surpassing $800 billion by then.</p><p>Much of what makes Lam Research unstoppable also applies to other semiconductor stocks like <b>Applied Materials</b> and <b>ASML Holding</b>. However, I&#39;ve highlighted Lam Research for this article because its valuation is the most attractive to me. It currently trades at a price-to-earnings (P/E) valuation of 23, which is within its historical range and a hair cheaper than that of top rival Applied Materials. And of these three stocks, it also pays the highest yielding dividend at 0.8%.</p><p>Of course, 0.8% from Lam Research isn&#39;t a high-yielding dividend by any means. But it&#39;s going up fast, having more than tripled over the past five years. And there&#39;s still plenty of room to grow.</p><p>One way to assess a company&#39;s ability to raise its dividend is by looking at its payout ratio -- the amount of earnings being used for dividends. Lam Research has a payout ratio of around 17%, whereas anything under 50% is typically considered to be conservative. In other words, Lam Research can more than double its dividend right now without stretching itself financially. Moreover, given what we&#39;ve seen, it should be able to grow its earnings over the next decade, providing even more breathing room for future dividend increases.</p><p>In closing, Axon Enterprise may have the highest upside of these three stocks. It currently has a market capitalization of just $11 billion despite a very big market opportunity. But Lam Research might be the safest of these three, given how indispensable semiconductors are for modern life and how high the barriers to entry are in the industry. Therefore, if you&#39;re frightened by current market uncertainty, you might consider Lam Research, assuming you&#39;re committed to buying and holding for the long term.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Stocks That Could Create Lasting Generational Wealth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Stocks That Could Create Lasting Generational Wealth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-29 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/29/3-unstoppable-stocks-that-could-create-lasting-gen/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Building generational wealth doesn't happen very often. Only 27% of people whose parents have college degrees have received an inheritance of any kind in 2019, according to the Federal Reserve's ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/29/3-unstoppable-stocks-that-could-create-lasting-gen/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4548":"巴美列捷福持仓","CAGR":"California Grapes International, Inc.","BK4551":"寇图资本持仓","BK4554":"元宇宙及AR概念","BK4567":"ESG概念","BK4543":"AI","AI":"C3.ai, Inc.","BK4147":"半导体设备","U":"Unity Software Inc.","AXON":"Axon Enterprise, Inc.","BK4528":"SaaS概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4023":"应用软件","BK4187":"航天航空与国防","LRCX":"拉姆研究"},"source_url":"https://www.fool.com/investing/2021/12/29/3-unstoppable-stocks-that-could-create-lasting-gen/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2195345230","content_text":"Building generational wealth doesn't happen very often. Only 27% of people whose parents have college degrees have received an inheritance of any kind in 2019, according to the Federal Reserve's Survey of Consumer Finances. If your parents didn't go to college, your odds are slightly worse. And the median inheritance received from college-degree parents was only $92,700. That amount is nothing to sneeze at, but there's taxes to think about. Moreover, this is the median inheritance. By definition, half of the people who did receive an inheritance received less than this.The point is, the vast majority of us haven't and probably won't be receiving generational wealth from our parents. And this reality from the past can't be changed. But we can do something about the future by building wealth to pass on to the next generation by saving and investing our own incomes now.Of course, if you're looking for stocks you can buy, hold, and pass on to your heirs, then you need to find companies that are unstoppable. For me, Unity Software (NYSE:U), Axon Enterprise (NASDAQ:AXON), and Lam Research (NASDAQ:LRCX) are three companies that might fit this description. These aren't necessarily three stocks with the highest upside. Indeed, they might struggle to beat the market average some years. But I do expect them to have greater longevity than many other stock options, so they're perfect for building generational wealth.Image source: Getty Images.Unity: The preferred platform to build the futureUnity offers easy-to-use software for creating three-dimensional (3D) content and developing ways for users to interact with these 3D images. Think broadly. This software has applications in gaming, animation, augmented reality, the metaverse, and more. And according to the company, over half of all 3D content built today is built using Unity.There's good reason to believe that Unity can keep its leadership position in the 3D space. Consider that the company doesn't charge people for its software if they're students or if their companies generate less than $100,000 in annual revenue. In other words, anyone new to the 3D game is very likely to choose Unity because it's the industry standard and -- more persuasively -- it's free. And once they create a viable business with over $100,000 in revenue, Unity can then start to profit as well.This kind of value proposition for new creators is going to make Unity hard to stop. Furthermore, consider something interesting with the company's business model: You can create mobile games, for example, with Unity. And creating things is recorded in the company's Create Solutions segment, a subscription-revenue product. But once games are created, you can also use Unity to operate them and get them monetized, etc. This revenue is recorded in its Operate Solutions segment, and it's not a straight subscription but rather a usage-based revenue model, meaning Unity makes more money as their customers succeed.Unity is likely to attract a lot of creators because of its value proposition. These can then stick with Unity to operate their digital content. And assuming Unity does a good job here, its revenue has uncapped upside because it's a usage-based revenue model. In the third quarter of 2021, Unity had a net-dollar expansion rate of 142%, which clearly demonstrates its customers are spending more money over time and its business model is working.According to Unity's management, only around 2% of the world's digital content is currently made in 3D. It's only reasonable to assume that this will increase substantially in coming years. I'll refrain from giving a set-in-stone forecast. But if 3D content had 5% to 10% share, it would still be a relatively small part of the overall market. And in this scenario, Unity could more than double its business just by maintaining its leadership position in the space.Image source: Axon Enterprise.Axon: Making work easy and switching hardIf Axon Enterprise only offered Tasers to police departments, then this would be a fragile business. But its decision to offer software solutions in conjunction with its hardware devices has made this an unstoppable business in my opinion. Here's why.Axon's Tasers are infrequent purchases with little recurring-revenue potential. But they do enjoy widespread adoption. In the U.S., 21% of law enforcement, federal, and corrections agencies, along with enterprises, are already Taser users, according to the company.Brilliantly, Axon leveraged its existing customer relationships into streams of recurring revenue when it decided to develop software solutions. Law enforcement officers can now automatically have evidence backed up to the cloud. And artificial-intelligence (AI) software can quickly fill out tedious paperwork. It's apparent its customers appreciate these software solutions because they're increasing spending, as measured by its 119% net-dollar retention rate in the third quarter of 2021. Moreover, Axon's hardware and software is increasingly a package deal. According to the company, 73% of total revenue in 2020 was tied to a subscription product.Axon Cloud is the fastest growing part of Axon's business these days. In Q3, software-as-a-service (SaaS) revenue was up almost 42% year over year compared to total revenue growth of just 39%. And management estimates its cloud-solutions product is still only 2% penetrated in the U.S. compared to the aforementioned 21% market penetration for Taser. This means Axon has a robust growth opportunity ahead just within its existing customer base, to say nothing of new customers.Once data is stored on the cloud, it's extremely inconvenient for customers to switch. This is the main reason I believe Axon is unstoppable. But the company also seems poised for more growth considering there's few companies -- if any -- that offer the broad suite of products that Axon does. The possibility of strong future growth was confirmed in Q3 with bookings. These represent spending commitments that can't be counted as revenue yet but are very likely to come in during future quarters. In Q3, Axon had bookings of $488 million, which was a quarterly record.Image source: Getty Images.Lam Research: Good luck trying to disrupt this oneHave you ever noticed how many carbonated beverage companies there are? One reason why there are so many is because it's relatively easy to create, package, and sell a drink. There's a low \"barrier to entry.\" However, when it comes to creating equipment to manufacture semiconductor products, the barrier to entry couldn't be higher, which is why Lam Research is unstoppable. It faces little risk of being disrupted by a newcomer anytime soon.Lam Research is a diversified business. That said, 64% of revenue comes from systems used for making memory products. Therefore, it's important to watch that segment of the industry. And in the near term, things are looking bright. Consider the outlook from memory company Micron Technology, which is a major industry player. Management from Micron just said it expects demand in 2022 to increase over 30% for NAND memory (flash memory) and over 20% for DRAM memory (dynamic random access memory) products. This suggests that Lam Research's services will be in hot demand in the coming year.Beyond 2022, things also look bright for Lam Research. Various third-party market research reports confirm the general upward trend of the semiconductor industry. One example comes from Precedence Research, which predicts the entire industry will grow at an almost 7% compound annual growth rate (CAGR) through 2030, surpassing $800 billion by then.Much of what makes Lam Research unstoppable also applies to other semiconductor stocks like Applied Materials and ASML Holding. However, I've highlighted Lam Research for this article because its valuation is the most attractive to me. It currently trades at a price-to-earnings (P/E) valuation of 23, which is within its historical range and a hair cheaper than that of top rival Applied Materials. And of these three stocks, it also pays the highest yielding dividend at 0.8%.Of course, 0.8% from Lam Research isn't a high-yielding dividend by any means. But it's going up fast, having more than tripled over the past five years. And there's still plenty of room to grow.One way to assess a company's ability to raise its dividend is by looking at its payout ratio -- the amount of earnings being used for dividends. Lam Research has a payout ratio of around 17%, whereas anything under 50% is typically considered to be conservative. In other words, Lam Research can more than double its dividend right now without stretching itself financially. Moreover, given what we've seen, it should be able to grow its earnings over the next decade, providing even more breathing room for future dividend increases.In closing, Axon Enterprise may have the highest upside of these three stocks. It currently has a market capitalization of just $11 billion despite a very big market opportunity. But Lam Research might be the safest of these three, given how indispensable semiconductors are for modern life and how high the barriers to entry are in the industry. Therefore, if you're frightened by current market uncertainty, you might consider Lam Research, assuming you're committed to buying and holding for the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":422,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696136585,"gmtCreate":1640648278195,"gmtModify":1640648278195,"author":{"id":"4094037277039370","authorId":"4094037277039370","name":"214455ec","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"Thanks","listText":"Thanks","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696136585","repostId":"1127544468","repostType":4,"repost":{"id":"1127544468","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640646504,"share":"https://www.laohu8.com/m/news/1127544468?lang=&edition=full","pubTime":"2021-12-28 07:08","market":"us","language":"en","title":"S&P 500 closes at record high on retail sales cheer","url":"https://stock-news.laohu8.com/highlight/detail?id=1127544468","media":"Reuters","summary":"Dec 27  - The S&P 500 indexended at a record high on Monday, its fourth straight session of gains, as strong U.S. retail sales underscored economic strength and eased worries from Omicron-driven flight cancellations that hit travel stocks.U.S. retail sales increased 8.5% year-over-year this holiday season, powered by an ecommerce boom, according to a Mastercard Inc report, giving the S&P 500 retailing indexa boost.Travel-related stocks, typically sensitive to coronavirus news, declined after U.S","content":"<p>Dec 27 (Reuters) - The S&amp;P 500 index(.SPX)ended at a record high on Monday, its fourth straight session of gains, as strong U.S. retail sales underscored economic strength and eased worries from Omicron-driven flight cancellations that hit travel stocks.</p>\n<p>U.S. retail sales increased 8.5% year-over-year this holiday season, powered by an ecommerce boom, according to a Mastercard Inc report, giving the S&amp;P 500 retailing index(.SPXRT)a boost.</p>\n<p>Travel-related stocks, typically sensitive to coronavirus news, declined after U.S. airlines canceled about 800 more flights on Monday after nixing thousands during the Christmas weekend, as Omicron cases soared.</p>\n<p>The S&amp;P 1500 airlines index&nbsp;shed 0.57%. Cruise operators <a href=\"https://laohu8.com/S/NCLH\">Norwegian Cruise Line</a> Holdings, <a href=\"https://laohu8.com/S/RGLD\">Royal</a> Caribbean(RCL.N)and <a href=\"https://laohu8.com/S/CCL\">Carnival</a> Corp(CCL.N)fell 2.55%, 1.35% and 1.18% respectively, among the biggest decliners on the benchmark S&amp;P 500.</p>\n<p>\"The market is in this interesting place where we have a strong consumer, with spending up 8% year over year. Personal consumption makes up 70% of our GDP, and that remains flush,\" said Sylvia Jablonski Kampaktsis, chief investment officer and co-founder at Defiance ETFs in <a href=\"https://laohu8.com/S/NWY\">New York</a>.</p>\n<p>\"Omicron reminds us that we still exist in this corona ecosystem. And it'll probably be <a href=\"https://laohu8.com/S/AONE.U\">one</a> of many things that we will continue talking about with this virus but the doomsday COVID scenario of 2020 feels like it's far behind us.\"</p>\n<p>All 11 main S&amp;P 500 sector indexes advanced, with energy(.SPNY)and tech(.SPLRCT)leading percentage gains.</p>\n<p>The Dow Jones Industrial Average(.DJI)rose 351.82 points, or 0.98%, to 36,302.38, the S&amp;P 500(.SPX)gained 65.4 points, or 1.38%, to 4,791.19 and the <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> Composite(.IXIC)added 217.89 points, or 1.39%, to 15,871.26.</p>\n<p>The S&amp;P 500 has climbed 4.9% during its recent run of gains, its biggest percentage gain over a four-day period since early November 2020.</p>\n<p>The Nasdaq Composite(.IXIC)got a boost from megacap companies, including Tesla Inc(TSLA.O), <a href=\"https://laohu8.com/S/MSFT\">Microsoft</a> Corp(MSFT.O), <a href=\"https://laohu8.com/S/AAPL\">Apple</a> Inc(AAPL.O)and <a href=\"https://laohu8.com/S/CASH\">Meta</a> Platform(FB.O).</p>\n<p>Main U.S. stock indexes are on track for a third straight yearly gain, with the benchmark S&amp;P 500(.SPX)poised for its best three-year performance since 1999.</p>\n<p>Volume on U.S. exchanges was 7.76 billion shares, compared with the 11.74 billion average for the full session over the last 20 trading days.</p>\n<p>Advancing issues outnumbered decliners on the NYSE by a 2.29-to-1 ratio; on Nasdaq, a 1.09-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 58 new 52-week highs and no new lows; the Nasdaq Composite recorded 101 new highs and 145 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500 closes at record high on retail sales cheer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500 closes at record high on retail sales cheer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-28 07:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 27 (Reuters) - The S&amp;P 500 index(.SPX)ended at a record high on Monday, its fourth straight session of gains, as strong U.S. retail sales underscored economic strength and eased worries from Omicron-driven flight cancellations that hit travel stocks.</p>\n<p>U.S. retail sales increased 8.5% year-over-year this holiday season, powered by an ecommerce boom, according to a Mastercard Inc report, giving the S&amp;P 500 retailing index(.SPXRT)a boost.</p>\n<p>Travel-related stocks, typically sensitive to coronavirus news, declined after U.S. airlines canceled about 800 more flights on Monday after nixing thousands during the Christmas weekend, as Omicron cases soared.</p>\n<p>The S&amp;P 1500 airlines index&nbsp;shed 0.57%. Cruise operators <a href=\"https://laohu8.com/S/NCLH\">Norwegian Cruise Line</a> Holdings, <a href=\"https://laohu8.com/S/RGLD\">Royal</a> Caribbean(RCL.N)and <a href=\"https://laohu8.com/S/CCL\">Carnival</a> Corp(CCL.N)fell 2.55%, 1.35% and 1.18% respectively, among the biggest decliners on the benchmark S&amp;P 500.</p>\n<p>\"The market is in this interesting place where we have a strong consumer, with spending up 8% year over year. Personal consumption makes up 70% of our GDP, and that remains flush,\" said Sylvia Jablonski Kampaktsis, chief investment officer and co-founder at Defiance ETFs in <a href=\"https://laohu8.com/S/NWY\">New York</a>.</p>\n<p>\"Omicron reminds us that we still exist in this corona ecosystem. And it'll probably be <a href=\"https://laohu8.com/S/AONE.U\">one</a> of many things that we will continue talking about with this virus but the doomsday COVID scenario of 2020 feels like it's far behind us.\"</p>\n<p>All 11 main S&amp;P 500 sector indexes advanced, with energy(.SPNY)and tech(.SPLRCT)leading percentage gains.</p>\n<p>The Dow Jones Industrial Average(.DJI)rose 351.82 points, or 0.98%, to 36,302.38, the S&amp;P 500(.SPX)gained 65.4 points, or 1.38%, to 4,791.19 and the <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> Composite(.IXIC)added 217.89 points, or 1.39%, to 15,871.26.</p>\n<p>The S&amp;P 500 has climbed 4.9% during its recent run of gains, its biggest percentage gain over a four-day period since early November 2020.</p>\n<p>The Nasdaq Composite(.IXIC)got a boost from megacap companies, including Tesla Inc(TSLA.O), <a href=\"https://laohu8.com/S/MSFT\">Microsoft</a> Corp(MSFT.O), <a href=\"https://laohu8.com/S/AAPL\">Apple</a> Inc(AAPL.O)and <a href=\"https://laohu8.com/S/CASH\">Meta</a> Platform(FB.O).</p>\n<p>Main U.S. stock indexes are on track for a third straight yearly gain, with the benchmark S&amp;P 500(.SPX)poised for its best three-year performance since 1999.</p>\n<p>Volume on U.S. exchanges was 7.76 billion shares, compared with the 11.74 billion average for the full session over the last 20 trading days.</p>\n<p>Advancing issues outnumbered decliners on the NYSE by a 2.29-to-1 ratio; on Nasdaq, a 1.09-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 58 new 52-week highs and no new lows; the Nasdaq Composite recorded 101 new highs and 145 new lows.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","SPXU":"三倍做空标普500ETF","BK4550":"红杉资本持仓","BK4559":"巴菲特持仓","BK4504":"桥水持仓","BK4534":"瑞士信贷持仓","SSO":"两倍做多标普500ETF","OEX":"标普100",".SPX":"S&P 500 Index","SDS":"两倍做空标普500ETF","UPRO":"三倍做多标普500ETF","SH":"标普500反向ETF","OEF":"标普100指数ETF-iShares","SPY":"标普500ETF","IVV":"标普500指数ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127544468","content_text":"Dec 27 (Reuters) - The S&P 500 index(.SPX)ended at a record high on Monday, its fourth straight session of gains, as strong U.S. retail sales underscored economic strength and eased worries from Omicron-driven flight cancellations that hit travel stocks.\nU.S. retail sales increased 8.5% year-over-year this holiday season, powered by an ecommerce boom, according to a Mastercard Inc report, giving the S&P 500 retailing index(.SPXRT)a boost.\nTravel-related stocks, typically sensitive to coronavirus news, declined after U.S. airlines canceled about 800 more flights on Monday after nixing thousands during the Christmas weekend, as Omicron cases soared.\nThe S&P 1500 airlines index shed 0.57%. Cruise operators Norwegian Cruise Line Holdings, Royal Caribbean(RCL.N)and Carnival Corp(CCL.N)fell 2.55%, 1.35% and 1.18% respectively, among the biggest decliners on the benchmark S&P 500.\n\"The market is in this interesting place where we have a strong consumer, with spending up 8% year over year. Personal consumption makes up 70% of our GDP, and that remains flush,\" said Sylvia Jablonski Kampaktsis, chief investment officer and co-founder at Defiance ETFs in New York.\n\"Omicron reminds us that we still exist in this corona ecosystem. And it'll probably be one of many things that we will continue talking about with this virus but the doomsday COVID scenario of 2020 feels like it's far behind us.\"\nAll 11 main S&P 500 sector indexes advanced, with energy(.SPNY)and tech(.SPLRCT)leading percentage gains.\nThe Dow Jones Industrial Average(.DJI)rose 351.82 points, or 0.98%, to 36,302.38, the S&P 500(.SPX)gained 65.4 points, or 1.38%, to 4,791.19 and the Nasdaq Composite(.IXIC)added 217.89 points, or 1.39%, to 15,871.26.\nThe S&P 500 has climbed 4.9% during its recent run of gains, its biggest percentage gain over a four-day period since early November 2020.\nThe Nasdaq Composite(.IXIC)got a boost from megacap companies, including Tesla Inc(TSLA.O), Microsoft Corp(MSFT.O), Apple Inc(AAPL.O)and Meta Platform(FB.O).\nMain U.S. stock indexes are on track for a third straight yearly gain, with the benchmark S&P 500(.SPX)poised for its best three-year performance since 1999.\nVolume on U.S. exchanges was 7.76 billion shares, compared with the 11.74 billion average for the full session over the last 20 trading days.\nAdvancing issues outnumbered decliners on the NYSE by a 2.29-to-1 ratio; on Nasdaq, a 1.09-to-1 ratio favored advancers.\nThe S&P 500 posted 58 new 52-week highs and no new lows; the Nasdaq Composite recorded 101 new highs and 145 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":473,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698728205,"gmtCreate":1640562084831,"gmtModify":1640562084831,"author":{"id":"4094037277039370","authorId":"4094037277039370","name":"214455ec","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"Thanks","listText":"Thanks","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698728205","repostId":"1132821017","repostType":4,"repost":{"id":"1132821017","pubTimestamp":1640393119,"share":"https://www.laohu8.com/m/news/1132821017?lang=&edition=full","pubTime":"2021-12-25 08:45","market":"us","language":"en","title":"S&P 5,000? Here's What Analysts And Investors Expect From The Stock Market In 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1132821017","media":"Benzinga","summary":"As 2021 winds to a close, investors and analysts are already shifting their focus to 2022. This year","content":"<p>As 2021 winds to a close, investors and analysts are already shifting their focus to 2022. This year marked the third consecutive year of at least 16% returns for the S&amp;P 500, leaving investors to wonder just how much more upside they can expect from the&nbsp;<b>SPDR S&amp;P 500 ETF Trust</b>(NYSE:SPY) in 2022.</p>\n<p><b>Landmark Target:</b>&nbsp;LPL Financial Chief Market Strategist Ryan Detrick recently said he’s optimistic about the potential for the S&amp;P 500 to hit the landmark 5,000 level in 2022.</p>\n<p>“We believe the S&amp;P 500 could be fairly valued at 5,000–5,100 at the end of 2022, based on an EPS estimate of $235 for 2023 and an index P/E between 21 and 21.5,” Detrick said in LPL’s 2022outlook report.</p>\n<p>Detrick said hitting and exceeding that price target range next year will hinge largely on corporate earnings. If interest rates stay lower for longer than the market expects, a strong economy and positive investor sentiment could support additional earnings upside and even further earnings multiple expansion, he said. However, if inflation, wage growth and rising interest rates pressure margins in 2022, Detrick said any S&amp;P 500 earnings growth at all may be hard to come by in 2022.</p>\n<p>For the S&amp;P 500 to hit 5,000, it will need to gain only about 6.2% from current levels, a relatively modest annual return for the index on a historical basis.</p>\n<p><b>Opportunities Ahead:</b>In his Daily Market Notes, Navellier CIO Louis Navellier recently said investors should continue to have opportunities in the market in 2022, but stock selection could become more important.</p>\n<p>“Although year-over-year earnings comparisons will become more difficult in 2022, a narrower market is good news for growth stocks and dividend growth stocks and bad news for the ‘index fund’ crowd, since growth stocks and dividend growth stocks have traditionally prospered in a narrowing, more selective, stock market environment like this,” Navellier said.</p>\n<p>He noted that Democrats are also likely to lose control of both the House of Representatives and the Senate in the 2022 midterm elections, and Wall Street has historically favored a divided government.</p>\n<p><b>Investor Survey Results:</b>&nbsp;DataTrek Research’s annual investor survey suggests investors are executing modest, positive returns from the S&amp;P 500 in 2022. In fact, 81% of investors surveyed are anticipating S&amp;P 500 returns in 2022 will be between 0% and 15% for the year, with 42% of respondents anticipating returns in the 5% to 10% range.</p>\n<p>“No wonder December is proving difficult, for if an investor thinks next year’s gains will be limited then selling ahead of a so-so year is a solid strategy,” DataTrek co-founder Nicholas Colas said.</p>\n<p>Colas recently pointed out that the aggregate 12-month price target for the S&amp;P 500 based on analysts’ single-stock price targets is 5,225.</p>\n<p><b>Benzinga’s Take:</b>&nbsp;It’s extremely difficult to predict what the stock market will do in any given year, but the S&amp;P 500’s long-term track record has been remarkably consistent throughout history. Since 1925, the rolling 35-year annual returns for the S&amp;P 500 have&nbsp;always stayed&nbsp;between around 8% and around 15%.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 5,000? Here's What Analysts And Investors Expect From The Stock Market In 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 5,000? Here's What Analysts And Investors Expect From The Stock Market In 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-25 08:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-ratings/analyst-color/21/12/24757408/s-p-5-000-heres-what-analysts-and-investors-expect-from-the-stock-market-in-2022><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As 2021 winds to a close, investors and analysts are already shifting their focus to 2022. This year marked the third consecutive year of at least 16% returns for the S&P 500, leaving investors to ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/21/12/24757408/s-p-5-000-heres-what-analysts-and-investors-expect-from-the-stock-market-in-2022\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index"},"source_url":"https://www.benzinga.com/analyst-ratings/analyst-color/21/12/24757408/s-p-5-000-heres-what-analysts-and-investors-expect-from-the-stock-market-in-2022","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1132821017","content_text":"As 2021 winds to a close, investors and analysts are already shifting their focus to 2022. This year marked the third consecutive year of at least 16% returns for the S&P 500, leaving investors to wonder just how much more upside they can expect from the SPDR S&P 500 ETF Trust(NYSE:SPY) in 2022.\nLandmark Target: LPL Financial Chief Market Strategist Ryan Detrick recently said he’s optimistic about the potential for the S&P 500 to hit the landmark 5,000 level in 2022.\n“We believe the S&P 500 could be fairly valued at 5,000–5,100 at the end of 2022, based on an EPS estimate of $235 for 2023 and an index P/E between 21 and 21.5,” Detrick said in LPL’s 2022outlook report.\nDetrick said hitting and exceeding that price target range next year will hinge largely on corporate earnings. If interest rates stay lower for longer than the market expects, a strong economy and positive investor sentiment could support additional earnings upside and even further earnings multiple expansion, he said. However, if inflation, wage growth and rising interest rates pressure margins in 2022, Detrick said any S&P 500 earnings growth at all may be hard to come by in 2022.\nFor the S&P 500 to hit 5,000, it will need to gain only about 6.2% from current levels, a relatively modest annual return for the index on a historical basis.\nOpportunities Ahead:In his Daily Market Notes, Navellier CIO Louis Navellier recently said investors should continue to have opportunities in the market in 2022, but stock selection could become more important.\n“Although year-over-year earnings comparisons will become more difficult in 2022, a narrower market is good news for growth stocks and dividend growth stocks and bad news for the ‘index fund’ crowd, since growth stocks and dividend growth stocks have traditionally prospered in a narrowing, more selective, stock market environment like this,” Navellier said.\nHe noted that Democrats are also likely to lose control of both the House of Representatives and the Senate in the 2022 midterm elections, and Wall Street has historically favored a divided government.\nInvestor Survey Results: DataTrek Research’s annual investor survey suggests investors are executing modest, positive returns from the S&P 500 in 2022. In fact, 81% of investors surveyed are anticipating S&P 500 returns in 2022 will be between 0% and 15% for the year, with 42% of respondents anticipating returns in the 5% to 10% range.\n“No wonder December is proving difficult, for if an investor thinks next year’s gains will be limited then selling ahead of a so-so year is a solid strategy,” DataTrek co-founder Nicholas Colas said.\nColas recently pointed out that the aggregate 12-month price target for the S&P 500 based on analysts’ single-stock price targets is 5,225.\nBenzinga’s Take: It’s extremely difficult to predict what the stock market will do in any given year, but the S&P 500’s long-term track record has been remarkably consistent throughout history. Since 1925, the rolling 35-year annual returns for the S&P 500 have always stayed between around 8% and around 15%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":444,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698542543,"gmtCreate":1640480241178,"gmtModify":1640480241178,"author":{"id":"4094037277039370","authorId":"4094037277039370","name":"214455ec","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698542543","repostId":"2194711211","repostType":4,"repost":{"id":"2194711211","pubTimestamp":1640479830,"share":"https://www.laohu8.com/m/news/2194711211?lang=&edition=full","pubTime":"2021-12-26 08:50","market":"us","language":"en","title":"7 Reasons the Stock Market Could Crash in January","url":"https://stock-news.laohu8.com/highlight/detail?id=2194711211","media":"Motley Fool","summary":"The new year could bring an end to what's been a nearly unstoppable 21-month rally in the S&P 500.","content":"<p>In less than a week, we'll officially be ringing in a new year. However, Wall Street might be sad to see 2021 come to a close. The benchmark <b>S&amp;P 500</b> (SNPINDEX:^GSPC) has more than doubled up (+24%) its average annual total return of 11% (including dividends) over the past four decades, and it hasn't undergone a steeper correction than 5%. It's been a true running of the bulls.</p>\n<p>But as we turn the page on 2021, it's quite possible Wall Street could lose its luster. Below are seven reasons the stock market could crash in January.</p>\n<h2>1. Omicron supply chain issues (domestic and abroad)</h2>\n<p>The most obvious obstacle for the S&amp;P 500 is the ongoing spread of coronavirus variants, of which omicron is now the most predominant in the United States. The issue is that there's no unified global approach as to how best to curtail omicron. Whereas some countries are now mandating vaccines, others are imposing few restrictions, if any.</p>\n<p>With a wide variance of mitigation measures being deployed, the single greatest risk to Wall Street is continued or brand-new supply chain issues. From tech and consumer goods to industrial companies, most sectors are at risk of operating shortfalls if global logistics continue to be tied into knots by the pandemic.</p>\n<h2>2. QE winding down</h2>\n<p>Another fairly obvious high-risk factor for Wall Street is the Federal Reserve going on the offensive against inflation. As a reminder, the Consumer Price Index for all Urban Consumers (CPI-U) rose 6.8% in November, which marked a 39-year high for inflation.</p>\n<p>Earlier this month, Federal Reserve Chairman Jerome Powell announced that the nation's central bank would expedite the winding down of its quantitative easing (QE) program. QE is the umbrella program responsible for buying long-term Treasury bonds (buying T-bonds pushes up their price and weighs down long-term yields) and mortgage-backed securities.</p>\n<p>Reduced bond buying should equate to higher borrowing rates, which in turn can slow the growth potential of previously fast-paced stocks.</p>\n<h2>3. Margin calls</h2>\n<p>Wall Street should also be deeply concerned about rapidly rising levels of margin debt, which is the amount of money that's been borrowed by institutions or investors <i>with interest</i> to purchase or short-sell securities.</p>\n<p>Over time, it's perfectly normal for the nominal amount of outstanding margin debt to climb. But since the March 2020 low, the amount of outstanding margin debt has come close to doubling, and now sits at nearly $919 billion, according to November data from the independent Financial Industry Regulatory Authority.</p>\n<p>There have only been three instances in the last 26 years where margin debt outstanding rose by at least 60% in a single year. It happened just months before the dot-com bubble burst, almost immediately ahead of the financial crisis, and in 2021. If stocks drift lower to begin the year, a margin-call wave could really accelerate things to the downside.</p>\n<h2>4. Sector rotation</h2>\n<p>Sometimes, the stock market dives for purely benign reasons. One such possibility is if we witness sector rotation in January. Sector rotation refers to investors moving money from one sector of the market to another.</p>\n<p>On the surface, you'd think a broad-based index like the S&amp;P 500 wouldn't be fazed by sector rotation. But it's no secret that growth stocks in the technology and healthcare sectors have been primarily leading this rally from the March 2020 bear market bottom. Now that we're well past the one-year mark since this bottom, it wouldn't be all that surprising to see investors locking in some profits on companies with valuation premiums and migrating some of their cash to safer/value investments or dividend plays.</p>\n<p>If investors do begin to choose value and dividends over growth stocks, there's little question the market-cap-weighted S&amp;P 500 will find itself under pressure.</p>\n<h2>5. Meme stock reversion</h2>\n<p>A fifth reason the stock market could crash in January is the potential for a dive in meme stocks, such as <b>AMC Entertainment Holdings</b>&nbsp;and <b>GameStop</b>.</p>\n<p>Even though these are grossly overvalued companies that have become detached from their respectively poor operating performances, the Fed noted in its semiannual Financial Stability Report that near- and long-term risks exist with the way young and novice investors have been putting their money to work.</p>\n<p>In particular, the report highlights that households invested in these social-media-driven stocks tend to have more-leveraged balance sheets. If common sense prevails and these bubble-like stocks begin to deflate, these leveraged investors may have no choice but to retreat, leading to increased market volatility.</p>\n<h2>6. Valuation</h2>\n<p>Even though valuation is rarely ever enough, by itself, to send the S&amp;P 500 screaming lower, historic precedents do suggest Wall Street may be in trouble come January.</p>\n<p>As of the closing bell on Dec. 21, the S&amp;P 500's Shiller price-to-earnings (P/E) ratio was 39. The Shiller P/E takes into account inflation-adjusted earnings over the past 10 years. Though the Shiller P/E multiple for the S&amp;P 500 has risen a bit since the advent of the internet in the mid-1990s, the current Shiller P/E is more than double its 151-year average of 16.9.</p>\n<p>What's far more worrisome is that the S&amp;P 500 has declined at least 20% in each of the previous four instances when the Shiller P/E surpassed 30. Wall Street simply doesn't have a good track record of supporting extreme valuations for long periods of time.</p>\n<h2>7. History makes its presence felt</h2>\n<p>Lastly, investors can look to history as another reason to be concerned about the broader market.</p>\n<p>Since 1960, there have been nine bear market declines (20% or more) for the S&amp;P 500. Following each of the previous eight bear market bottoms (i.e., not including the coronavirus crash), the S&amp;P 500 underwent either one or two double-digit percentage declines in the subsequent 36 months. We're now 21 months removed from the March 2020 bear market low and haven't come close to a double-digit correction in the broad-market index.</p>\n<p>Keep in mind that if a stock market crash or correction does occur in January, it would represent a fantastic buying opportunity for long-term investors. Just be aware that crashes and corrections are the price of admission to one of the world's greatest wealth creators.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Reasons the Stock Market Could Crash in January</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Reasons the Stock Market Could Crash in January\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-26 08:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/25/7-reasons-the-stock-market-could-crash-in-january/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In less than a week, we'll officially be ringing in a new year. However, Wall Street might be sad to see 2021 come to a close. The benchmark S&P 500 (SNPINDEX:^GSPC) has more than doubled up (+24%) ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/25/7-reasons-the-stock-market-could-crash-in-january/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","UPRO":"三倍做多标普500ETF","SDS":"两倍做空标普500ETF","SH":"标普500反向ETF","OEX":"标普100",".SPX":"S&P 500 Index","SPY":"标普500ETF","BK4559":"巴菲特持仓","SSO":"两倍做多标普500ETF","BK4534":"瑞士信贷持仓","IVV":"标普500指数ETF","OEF":"标普100指数ETF-iShares","BK4550":"红杉资本持仓","SPXU":"三倍做空标普500ETF","BK4504":"桥水持仓"},"source_url":"https://www.fool.com/investing/2021/12/25/7-reasons-the-stock-market-could-crash-in-january/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2194711211","content_text":"In less than a week, we'll officially be ringing in a new year. However, Wall Street might be sad to see 2021 come to a close. The benchmark S&P 500 (SNPINDEX:^GSPC) has more than doubled up (+24%) its average annual total return of 11% (including dividends) over the past four decades, and it hasn't undergone a steeper correction than 5%. It's been a true running of the bulls.\nBut as we turn the page on 2021, it's quite possible Wall Street could lose its luster. Below are seven reasons the stock market could crash in January.\n1. Omicron supply chain issues (domestic and abroad)\nThe most obvious obstacle for the S&P 500 is the ongoing spread of coronavirus variants, of which omicron is now the most predominant in the United States. The issue is that there's no unified global approach as to how best to curtail omicron. Whereas some countries are now mandating vaccines, others are imposing few restrictions, if any.\nWith a wide variance of mitigation measures being deployed, the single greatest risk to Wall Street is continued or brand-new supply chain issues. From tech and consumer goods to industrial companies, most sectors are at risk of operating shortfalls if global logistics continue to be tied into knots by the pandemic.\n2. QE winding down\nAnother fairly obvious high-risk factor for Wall Street is the Federal Reserve going on the offensive against inflation. As a reminder, the Consumer Price Index for all Urban Consumers (CPI-U) rose 6.8% in November, which marked a 39-year high for inflation.\nEarlier this month, Federal Reserve Chairman Jerome Powell announced that the nation's central bank would expedite the winding down of its quantitative easing (QE) program. QE is the umbrella program responsible for buying long-term Treasury bonds (buying T-bonds pushes up their price and weighs down long-term yields) and mortgage-backed securities.\nReduced bond buying should equate to higher borrowing rates, which in turn can slow the growth potential of previously fast-paced stocks.\n3. Margin calls\nWall Street should also be deeply concerned about rapidly rising levels of margin debt, which is the amount of money that's been borrowed by institutions or investors with interest to purchase or short-sell securities.\nOver time, it's perfectly normal for the nominal amount of outstanding margin debt to climb. But since the March 2020 low, the amount of outstanding margin debt has come close to doubling, and now sits at nearly $919 billion, according to November data from the independent Financial Industry Regulatory Authority.\nThere have only been three instances in the last 26 years where margin debt outstanding rose by at least 60% in a single year. It happened just months before the dot-com bubble burst, almost immediately ahead of the financial crisis, and in 2021. If stocks drift lower to begin the year, a margin-call wave could really accelerate things to the downside.\n4. Sector rotation\nSometimes, the stock market dives for purely benign reasons. One such possibility is if we witness sector rotation in January. Sector rotation refers to investors moving money from one sector of the market to another.\nOn the surface, you'd think a broad-based index like the S&P 500 wouldn't be fazed by sector rotation. But it's no secret that growth stocks in the technology and healthcare sectors have been primarily leading this rally from the March 2020 bear market bottom. Now that we're well past the one-year mark since this bottom, it wouldn't be all that surprising to see investors locking in some profits on companies with valuation premiums and migrating some of their cash to safer/value investments or dividend plays.\nIf investors do begin to choose value and dividends over growth stocks, there's little question the market-cap-weighted S&P 500 will find itself under pressure.\n5. Meme stock reversion\nA fifth reason the stock market could crash in January is the potential for a dive in meme stocks, such as AMC Entertainment Holdings and GameStop.\nEven though these are grossly overvalued companies that have become detached from their respectively poor operating performances, the Fed noted in its semiannual Financial Stability Report that near- and long-term risks exist with the way young and novice investors have been putting their money to work.\nIn particular, the report highlights that households invested in these social-media-driven stocks tend to have more-leveraged balance sheets. If common sense prevails and these bubble-like stocks begin to deflate, these leveraged investors may have no choice but to retreat, leading to increased market volatility.\n6. Valuation\nEven though valuation is rarely ever enough, by itself, to send the S&P 500 screaming lower, historic precedents do suggest Wall Street may be in trouble come January.\nAs of the closing bell on Dec. 21, the S&P 500's Shiller price-to-earnings (P/E) ratio was 39. The Shiller P/E takes into account inflation-adjusted earnings over the past 10 years. Though the Shiller P/E multiple for the S&P 500 has risen a bit since the advent of the internet in the mid-1990s, the current Shiller P/E is more than double its 151-year average of 16.9.\nWhat's far more worrisome is that the S&P 500 has declined at least 20% in each of the previous four instances when the Shiller P/E surpassed 30. Wall Street simply doesn't have a good track record of supporting extreme valuations for long periods of time.\n7. History makes its presence felt\nLastly, investors can look to history as another reason to be concerned about the broader market.\nSince 1960, there have been nine bear market declines (20% or more) for the S&P 500. Following each of the previous eight bear market bottoms (i.e., not including the coronavirus crash), the S&P 500 underwent either one or two double-digit percentage declines in the subsequent 36 months. We're now 21 months removed from the March 2020 bear market low and haven't come close to a double-digit correction in the broad-market index.\nKeep in mind that if a stock market crash or correction does occur in January, it would represent a fantastic buying opportunity for long-term investors. Just be aware that crashes and corrections are the price of admission to one of the world's greatest wealth creators.","news_type":1},"isVote":1,"tweetType":1,"viewCount":612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698621483,"gmtCreate":1640388863343,"gmtModify":1640388863343,"author":{"id":"4094037277039370","authorId":"4094037277039370","name":"214455ec","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698621483","repostId":"1122704248","repostType":4,"repost":{"id":"1122704248","pubTimestamp":1640346833,"share":"https://www.laohu8.com/m/news/1122704248?lang=&edition=full","pubTime":"2021-12-24 19:53","market":"us","language":"en","title":"3 Charts to Consider if You Want to Own an EV Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1122704248","media":"Motley Fool","summary":"There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some","content":"<p>There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some stocks have been exceptional over the last two years. Now, the landscape for the sector seems to be clearing so investors can get a better idea of who the players are, and over what time frame EV makers will be bringing out new offerings.</p>\n<p>Beyond just looking at the exciting new products and potentially huge market,investors should research&nbsp;details that will help compare and contrast the EV makers. If you're interested in diving in now, the three charts below will provide a look at some data worth considering before you make an investment.</p>\n<p><b>Returns have been unpredictable</b></p>\n<p>Many have bought into the EV sector looking for large, market-beating returns. While shares of EV leader<b>Tesla</b>(NASDAQ:TSLA)skyrocketed last year, as the field of publicly traded names has grown, returns have been inconsistent. And investors need to be prepared for plenty of volatility along the way. The chart below shows the most recent six-month returns from a mix of U.S.- and China-based EV makers:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/628cf15ff39a9f1a896ba56a7db9020d\" tg-width=\"720\" tg-height=\"387\" width=\"100%\" height=\"auto\"><span>DATA BYYCHARTS.</span></p>\n<p>Even the strong returns from Tesla and&nbsp;<b>Lucid Group</b>(NASDAQ:LCID)stocks have included big swings in just the past two months. And though Chinese EV makers&nbsp;<b>Nio</b>(NYSE:NIO)&nbsp;and&nbsp;<b>XPeng</b>(NYSE:XPEV)have been growing sales quickly, their stocks have backtracked since June 2021.<b>Lordstown Motors</b>(NASDAQ:RIDE), maker of the Endurance all-electric work truck, has struggled, and shareholders have paid the price this year. The lesson is that there will be winners and losers, and EV stock moves can be quick and extreme.</p>\n<p><b>There's plenty of demand</b></p>\n<p>Just looking at share-price movement doesn't tell the full story, of course. While Nio and XPeng shares haven't moved higher in the last half-year, both company's sales skyrocketed over the first nine months of 2021, as shown below:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7a2201193c16f33bc21f52f5aacebbea\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>DATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.*XPENG 2021 COMPARISON WITH FINAL THREE QUARTERS OF 2020.</span></p>\n<p>Tesla has almost doubled its deliveries over the first nine months of 2021 compared to the year-ago period. But XPeng andNio deliveries are growing much faster, though the two Chinese companies are growing off of a much smaller base. And as both are already richly valued, with recent&nbsp;market capitalizations&nbsp;of around $36 billion and $48 billion, respectively, investors have sold off shares in recent months. Global demand is strong and growing, but that won't automatically result in growing share prices.</p>\n<p><b>Profitability will take time</b></p>\n<p>Investors in any business need to focus on the bottom line. Early stage growth companies aren't necessarily expected to become profitable quickly, however. Especially with a high-fixed-cost business like automotive manufacturing, profits will only come with scale. As the chart below shows, few EV makers are bringing in profits yet:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/32eab03a7b97ed8deb8757e127924d51\" tg-width=\"700\" tg-height=\"495\" width=\"100%\" height=\"auto\"><span>DATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.</span></p>\n<p>Tesla led the industry with a reported profit of more than $1.6 billion in the third quarter of 2021 .</p>\n<p>BYD is perhaps a less well-known Chinese EV company, and it sells more than just&nbsp;electric cars; it also makes batteries, electric buses, and traditional internal combustion vehicles. But its \"new energy vehicles\" -- which include plug-in hybrid electrics -- made up more than 90% of the nearly 100,000 new energy passenger vehicles it delivered in November.</p>\n<p>Lucid and&nbsp;<b>Rivian Automotive</b>(NASDAQ:RIVN)are getting a lot of attention recently, but they've barely started shipping product; the losses there will continue for some time until those companies reach scale. Investors hope that Nio and XPeng reach profitability soon, as both are growing sales and expanding product offerings. But investors interested in the sector need to be prepared for a long road before profitability can be expected.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Charts to Consider if You Want to Own an EV Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Charts to Consider if You Want to Own an EV Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 19:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/24/3-charts-to-consider-to-own-an-ev-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some stocks have been exceptional over the last two years. Now, the landscape for the sector seems to be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/3-charts-to-consider-to-own-an-ev-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","LCID":"Lucid Group Inc","TSLA":"特斯拉","XPEV":"小鹏汽车","RIVN":"Rivian Automotive, Inc."},"source_url":"https://www.fool.com/investing/2021/12/24/3-charts-to-consider-to-own-an-ev-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122704248","content_text":"There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some stocks have been exceptional over the last two years. Now, the landscape for the sector seems to be clearing so investors can get a better idea of who the players are, and over what time frame EV makers will be bringing out new offerings.\nBeyond just looking at the exciting new products and potentially huge market,investors should research details that will help compare and contrast the EV makers. If you're interested in diving in now, the three charts below will provide a look at some data worth considering before you make an investment.\nReturns have been unpredictable\nMany have bought into the EV sector looking for large, market-beating returns. While shares of EV leaderTesla(NASDAQ:TSLA)skyrocketed last year, as the field of publicly traded names has grown, returns have been inconsistent. And investors need to be prepared for plenty of volatility along the way. The chart below shows the most recent six-month returns from a mix of U.S.- and China-based EV makers:\nDATA BYYCHARTS.\nEven the strong returns from Tesla and Lucid Group(NASDAQ:LCID)stocks have included big swings in just the past two months. And though Chinese EV makers Nio(NYSE:NIO) and XPeng(NYSE:XPEV)have been growing sales quickly, their stocks have backtracked since June 2021.Lordstown Motors(NASDAQ:RIDE), maker of the Endurance all-electric work truck, has struggled, and shareholders have paid the price this year. The lesson is that there will be winners and losers, and EV stock moves can be quick and extreme.\nThere's plenty of demand\nJust looking at share-price movement doesn't tell the full story, of course. While Nio and XPeng shares haven't moved higher in the last half-year, both company's sales skyrocketed over the first nine months of 2021, as shown below:\nDATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.*XPENG 2021 COMPARISON WITH FINAL THREE QUARTERS OF 2020.\nTesla has almost doubled its deliveries over the first nine months of 2021 compared to the year-ago period. But XPeng andNio deliveries are growing much faster, though the two Chinese companies are growing off of a much smaller base. And as both are already richly valued, with recent market capitalizations of around $36 billion and $48 billion, respectively, investors have sold off shares in recent months. Global demand is strong and growing, but that won't automatically result in growing share prices.\nProfitability will take time\nInvestors in any business need to focus on the bottom line. Early stage growth companies aren't necessarily expected to become profitable quickly, however. Especially with a high-fixed-cost business like automotive manufacturing, profits will only come with scale. As the chart below shows, few EV makers are bringing in profits yet:\nDATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.\nTesla led the industry with a reported profit of more than $1.6 billion in the third quarter of 2021 .\nBYD is perhaps a less well-known Chinese EV company, and it sells more than just electric cars; it also makes batteries, electric buses, and traditional internal combustion vehicles. But its \"new energy vehicles\" -- which include plug-in hybrid electrics -- made up more than 90% of the nearly 100,000 new energy passenger vehicles it delivered in November.\nLucid and Rivian Automotive(NASDAQ:RIVN)are getting a lot of attention recently, but they've barely started shipping product; the losses there will continue for some time until those companies reach scale. Investors hope that Nio and XPeng reach profitability soon, as both are growing sales and expanding product offerings. But investors interested in the sector need to be prepared for a long road before profitability can be expected.","news_type":1},"isVote":1,"tweetType":1,"viewCount":497,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698371756,"gmtCreate":1640311503014,"gmtModify":1640313145337,"author":{"id":"4094037277039370","authorId":"4094037277039370","name":"214455ec","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"It's going to be another bumper year for Pfizer","listText":"It's going to be another bumper year for Pfizer","text":"It's going to be another bumper year for Pfizer","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698371756","repostId":"1110395878","repostType":4,"isVote":1,"tweetType":1,"viewCount":387,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691530854,"gmtCreate":1640218928679,"gmtModify":1640218928679,"author":{"id":"4094037277039370","authorId":"4094037277039370","name":"214455ec","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"This will help the economy to avoid lock downs&nbsp;","listText":"This will help the economy to avoid lock downs&nbsp;","text":"This will help the economy to avoid lock downs","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691530854","repostId":"1131862374","repostType":4,"repost":{"id":"1131862374","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640213195,"share":"https://www.laohu8.com/m/news/1131862374?lang=&edition=full","pubTime":"2021-12-23 06:46","market":"us","language":"en","title":"U.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use","url":"https://stock-news.laohu8.com/highlight/detail?id=1131862374","media":"Reuters","summary":"Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's antiviral COVID-19 pill fo","content":"<p>Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's&nbsp;antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading&nbsp;Omicron variant.</p>\n<p>Pfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.</p>\n<p>Pfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.</p>\n<p>\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.</p>\n<p>\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.</p>\n<p>Pfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.</p>\n<p>The Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing&nbsp;plans for more federal&nbsp;vaccination and testing sites.</p>\n<p>The pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.</p>\n<p>Monoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.</p>\n<p>The Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.</p>\n<p>The FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.</p>\n<p>The drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA&nbsp;said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.</p>\n<p>While the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).</p>\n<p>The second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.</p>\n<p>Pfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.</p>\n<p>Pfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.</p>\n<p>A rival pill from Merck &amp; Co&nbsp;is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-23 06:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's&nbsp;antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading&nbsp;Omicron variant.</p>\n<p>Pfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.</p>\n<p>Pfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.</p>\n<p>\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.</p>\n<p>\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.</p>\n<p>Pfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.</p>\n<p>The Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing&nbsp;plans for more federal&nbsp;vaccination and testing sites.</p>\n<p>The pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.</p>\n<p>Monoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.</p>\n<p>The Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.</p>\n<p>The FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.</p>\n<p>The drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA&nbsp;said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.</p>\n<p>While the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).</p>\n<p>The second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.</p>\n<p>Pfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.</p>\n<p>Pfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.</p>\n<p>A rival pill from Merck &amp; Co&nbsp;is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131862374","content_text":"Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading Omicron variant.\nPfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.\nPfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.\n\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.\n\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.\nPfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.\nThe Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing plans for more federal vaccination and testing sites.\nThe pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.\nMonoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.\nThe Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.\nThe FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.\nThe drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.\nWhile the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).\nThe second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.\nPfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.\nPfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.\nA rival pill from Merck & Co is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.","news_type":1},"isVote":1,"tweetType":1,"viewCount":866,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691597279,"gmtCreate":1640218842725,"gmtModify":1640218842725,"author":{"id":"4094037277039370","authorId":"4094037277039370","name":"214455ec","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"This will be interesting since she's fighting the dominant power of Big Tech","listText":"This will be interesting since she's fighting the dominant power of Big Tech","text":"This will be interesting since she's fighting the dominant power of Big Tech","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/691597279","repostId":"2193186771","repostType":4,"isVote":1,"tweetType":1,"viewCount":469,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693288899,"gmtCreate":1640040641714,"gmtModify":1640054165666,"author":{"id":"4094037277039370","authorId":"4094037277039370","name":"214455ec","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"BB in play to buy stocks cheap again","listText":"BB in play to buy stocks cheap again","text":"BB in play to buy stocks cheap again","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":15,"commentSize":10,"repostSize":0,"link":"https://laohu8.com/post/693288899","repostId":"1139958745","repostType":4,"isVote":1,"tweetType":1,"viewCount":379,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000462","authorId":"9000000000000462","name":"MyrnaNorth","avatar":"https://static.tigerbbs.com/58e77982f280b570830d1b8273d6de7e","crmLevel":1,"crmLevelSwitch":0},"content":"BB很可能会超出预期，但市场希望看到的增长再次没有出现。就像在上一个CC中一样，我们只能希望J陈会有一些好消息。标普已经将其考虑在内，但没有好消息显示，未来3个月，标普的股价将再次升至9-10美元。这只是我自己的看法。","text":"BB很可能会超出预期，但市场希望看到的增长再次没有出现。就像在上一个CC中一样，我们只能希望J陈会有一些好消息。标普已经将其考虑在内，但没有好消息显示，未来3个月，标普的股价将再次升至9-10美元。这只是我自己的看法。","html":"BB很可能会超出预期，但市场希望看到的增长再次没有出现。就像在上一个CC中一样，我们只能希望J陈会有一些好消息。标普已经将其考虑在内，但没有好消息显示，未来3个月，标普的股价将再次升至9-10美元。这只是我自己的看法。"}],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":693288899,"gmtCreate":1640040641714,"gmtModify":1640054165666,"author":{"id":"4094037277039370","authorId":"4094037277039370","name":"214455ec","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"BB in play to buy stocks cheap again","listText":"BB in play to buy stocks cheap again","text":"BB in play to buy stocks cheap again","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":15,"commentSize":10,"repostSize":0,"link":"https://laohu8.com/post/693288899","repostId":"1139958745","repostType":4,"repost":{"id":"1139958745","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640010639,"share":"https://www.laohu8.com/m/news/1139958745?lang=&edition=full","pubTime":"2021-12-20 22:30","market":"us","language":"en","title":"Dow falls 500 points to start the week as omicron continues to spook markets","url":"https://stock-news.laohu8.com/highlight/detail?id=1139958745","media":"Tiger Newspress","summary":"Stocks fell on Monday at the start of a holiday-shortened week of trading, with investors considerin","content":"<p>Stocks fell on Monday at&nbsp;the start of a holiday-shortened week of trading, with investors considering renewed virus-related restrictions overseas and prospects that a significant social policy bill may be scuttled.</p>\n<p>The S&amp;P 500, Dow Nasdaq each dropped more than 1%. Treasury yields fell as investors piled into safe haven assets, and the benchmark 10-year yield held below 1.4%. The CBOE Volatility Index,or VIX,spiked more than 20% to hover above 25.</p>\n<p>U.S. crude oil prices sank 3% to trade below $69 per barrel as restrictions mounted in Europe, stoking jitters around energy demand. Countries from&nbsp;Germany to Irelandimposed curfews or travel restrictions in recent days given the rapidly spreading new variant. And the Netherlands over the weekend&nbsp;announced a nationwide lockdown of non-essential stores, bars and restaurants&nbsp;until Jan. 14. As of this weekend, the Omicron variant&nbsp;had been reported in about 89 countries,with cases doubling every 1.5 to 3 days.</p>\n<p>Renewed fears over the economic impact of the Omicron variant compounded with last week's concerns for investors around the prospects of tighter monetary policy, with the Federal Reserve accelerating its rate of asset-purchase tapering and signaling three interest rate hikes could be coming next year. Last week, each of the three major indexes posted steep weekly losses. The Nasdaq Composite fell 3% and the S&amp;P 500 and Dow each dropped by nearly 2% for the week.</p>\n<p>Still, other updates around the effect of current COVID-19 vaccines on the variant were more upbeat. Moderna (MRNA)said Monday that a booster,or a third dose, of its shot increased Omicron neutralizing antibody levels. This echoed results from&nbsp;Pfizer (PFE) and BioNTech (BNTX) from earlier this month&nbsp;about the effectiveness of their vaccine's third dose on neutralizing Omicron. Shares of Moderna gained more than 7% ahead of the opening bell.</p>\n<p>Investors also digested the unexpected news that Senator Joe Manchin (D., W. Va.) would not support President Joe Biden's $1.75 billion Build Back Better social policy bill. Manchin, speaking onFox News Sunday, said he had discussed with Democratic House and Senate leaders and Biden, but was unable to come to an agreement on the bill given concerns about inflation, the national debt and ongoing pandemic.</p>\n<p>White House Press Secretary Jen Psakireleased a statement&nbsp;calling Manchin's comments \"a sudden and inexplicable reversal in his position,\" and said the administration would work to move forward with the legislation next year.</p>\n<p>Still, Goldman Sachs this weekend&nbsp;slashed its quarter GDP forecasts for 2022following Manchin's withdrawal of support for the bill. The economists, led by Jan Hatzius, said they expected the \"fiscal impulse will be somewhat more negative\" than previously expected next year, in absence of the spending on social and climate-related policies included in the bill. The firm lowered its U.S. GDP forecast to 2% from 3% for the first quarter of 2022, to 3% from 3.5% for the second quarter, and to 2.75% from 3% for the third quarter.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dow falls 500 points to start the week as omicron continues to spook markets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDow falls 500 points to start the week as omicron continues to spook markets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-20 22:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Stocks fell on Monday at&nbsp;the start of a holiday-shortened week of trading, with investors considering renewed virus-related restrictions overseas and prospects that a significant social policy bill may be scuttled.</p>\n<p>The S&amp;P 500, Dow Nasdaq each dropped more than 1%. Treasury yields fell as investors piled into safe haven assets, and the benchmark 10-year yield held below 1.4%. The CBOE Volatility Index,or VIX,spiked more than 20% to hover above 25.</p>\n<p>U.S. crude oil prices sank 3% to trade below $69 per barrel as restrictions mounted in Europe, stoking jitters around energy demand. Countries from&nbsp;Germany to Irelandimposed curfews or travel restrictions in recent days given the rapidly spreading new variant. And the Netherlands over the weekend&nbsp;announced a nationwide lockdown of non-essential stores, bars and restaurants&nbsp;until Jan. 14. As of this weekend, the Omicron variant&nbsp;had been reported in about 89 countries,with cases doubling every 1.5 to 3 days.</p>\n<p>Renewed fears over the economic impact of the Omicron variant compounded with last week's concerns for investors around the prospects of tighter monetary policy, with the Federal Reserve accelerating its rate of asset-purchase tapering and signaling three interest rate hikes could be coming next year. Last week, each of the three major indexes posted steep weekly losses. The Nasdaq Composite fell 3% and the S&amp;P 500 and Dow each dropped by nearly 2% for the week.</p>\n<p>Still, other updates around the effect of current COVID-19 vaccines on the variant were more upbeat. Moderna (MRNA)said Monday that a booster,or a third dose, of its shot increased Omicron neutralizing antibody levels. This echoed results from&nbsp;Pfizer (PFE) and BioNTech (BNTX) from earlier this month&nbsp;about the effectiveness of their vaccine's third dose on neutralizing Omicron. Shares of Moderna gained more than 7% ahead of the opening bell.</p>\n<p>Investors also digested the unexpected news that Senator Joe Manchin (D., W. Va.) would not support President Joe Biden's $1.75 billion Build Back Better social policy bill. Manchin, speaking onFox News Sunday, said he had discussed with Democratic House and Senate leaders and Biden, but was unable to come to an agreement on the bill given concerns about inflation, the national debt and ongoing pandemic.</p>\n<p>White House Press Secretary Jen Psakireleased a statement&nbsp;calling Manchin's comments \"a sudden and inexplicable reversal in his position,\" and said the administration would work to move forward with the legislation next year.</p>\n<p>Still, Goldman Sachs this weekend&nbsp;slashed its quarter GDP forecasts for 2022following Manchin's withdrawal of support for the bill. The economists, led by Jan Hatzius, said they expected the \"fiscal impulse will be somewhat more negative\" than previously expected next year, in absence of the spending on social and climate-related policies included in the bill. The firm lowered its U.S. GDP forecast to 2% from 3% for the first quarter of 2022, to 3% from 3.5% for the second quarter, and to 2.75% from 3% for the third quarter.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139958745","content_text":"Stocks fell on Monday at the start of a holiday-shortened week of trading, with investors considering renewed virus-related restrictions overseas and prospects that a significant social policy bill may be scuttled.\nThe S&P 500, Dow Nasdaq each dropped more than 1%. Treasury yields fell as investors piled into safe haven assets, and the benchmark 10-year yield held below 1.4%. The CBOE Volatility Index,or VIX,spiked more than 20% to hover above 25.\nU.S. crude oil prices sank 3% to trade below $69 per barrel as restrictions mounted in Europe, stoking jitters around energy demand. Countries from Germany to Irelandimposed curfews or travel restrictions in recent days given the rapidly spreading new variant. And the Netherlands over the weekend announced a nationwide lockdown of non-essential stores, bars and restaurants until Jan. 14. As of this weekend, the Omicron variant had been reported in about 89 countries,with cases doubling every 1.5 to 3 days.\nRenewed fears over the economic impact of the Omicron variant compounded with last week's concerns for investors around the prospects of tighter monetary policy, with the Federal Reserve accelerating its rate of asset-purchase tapering and signaling three interest rate hikes could be coming next year. Last week, each of the three major indexes posted steep weekly losses. The Nasdaq Composite fell 3% and the S&P 500 and Dow each dropped by nearly 2% for the week.\nStill, other updates around the effect of current COVID-19 vaccines on the variant were more upbeat. Moderna (MRNA)said Monday that a booster,or a third dose, of its shot increased Omicron neutralizing antibody levels. This echoed results from Pfizer (PFE) and BioNTech (BNTX) from earlier this month about the effectiveness of their vaccine's third dose on neutralizing Omicron. Shares of Moderna gained more than 7% ahead of the opening bell.\nInvestors also digested the unexpected news that Senator Joe Manchin (D., W. Va.) would not support President Joe Biden's $1.75 billion Build Back Better social policy bill. Manchin, speaking onFox News Sunday, said he had discussed with Democratic House and Senate leaders and Biden, but was unable to come to an agreement on the bill given concerns about inflation, the national debt and ongoing pandemic.\nWhite House Press Secretary Jen Psakireleased a statement calling Manchin's comments \"a sudden and inexplicable reversal in his position,\" and said the administration would work to move forward with the legislation next year.\nStill, Goldman Sachs this weekend slashed its quarter GDP forecasts for 2022following Manchin's withdrawal of support for the bill. The economists, led by Jan Hatzius, said they expected the \"fiscal impulse will be somewhat more negative\" than previously expected next year, in absence of the spending on social and climate-related policies included in the bill. The firm lowered its U.S. GDP forecast to 2% from 3% for the first quarter of 2022, to 3% from 3.5% for the second quarter, and to 2.75% from 3% for the third quarter.","news_type":1},"isVote":1,"tweetType":1,"viewCount":379,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000462","authorId":"9000000000000462","name":"MyrnaNorth","avatar":"https://static.tigerbbs.com/58e77982f280b570830d1b8273d6de7e","crmLevel":1,"crmLevelSwitch":0},"content":"BB很可能会超出预期，但市场希望看到的增长再次没有出现。就像在上一个CC中一样，我们只能希望J陈会有一些好消息。标普已经将其考虑在内，但没有好消息显示，未来3个月，标普的股价将再次升至9-10美元。这只是我自己的看法。","text":"BB很可能会超出预期，但市场希望看到的增长再次没有出现。就像在上一个CC中一样，我们只能希望J陈会有一些好消息。标普已经将其考虑在内，但没有好消息显示，未来3个月，标普的股价将再次升至9-10美元。这只是我自己的看法。","html":"BB很可能会超出预期，但市场希望看到的增长再次没有出现。就像在上一个CC中一样，我们只能希望J陈会有一些好消息。标普已经将其考虑在内，但没有好消息显示，未来3个月，标普的股价将再次升至9-10美元。这只是我自己的看法。"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698542543,"gmtCreate":1640480241178,"gmtModify":1640480241178,"author":{"id":"4094037277039370","authorId":"4094037277039370","name":"214455ec","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698542543","repostId":"2194711211","repostType":4,"repost":{"id":"2194711211","pubTimestamp":1640479830,"share":"https://www.laohu8.com/m/news/2194711211?lang=&edition=full","pubTime":"2021-12-26 08:50","market":"us","language":"en","title":"7 Reasons the Stock Market Could Crash in January","url":"https://stock-news.laohu8.com/highlight/detail?id=2194711211","media":"Motley Fool","summary":"The new year could bring an end to what's been a nearly unstoppable 21-month rally in the S&P 500.","content":"<p>In less than a week, we'll officially be ringing in a new year. However, Wall Street might be sad to see 2021 come to a close. The benchmark <b>S&amp;P 500</b> (SNPINDEX:^GSPC) has more than doubled up (+24%) its average annual total return of 11% (including dividends) over the past four decades, and it hasn't undergone a steeper correction than 5%. It's been a true running of the bulls.</p>\n<p>But as we turn the page on 2021, it's quite possible Wall Street could lose its luster. Below are seven reasons the stock market could crash in January.</p>\n<h2>1. Omicron supply chain issues (domestic and abroad)</h2>\n<p>The most obvious obstacle for the S&amp;P 500 is the ongoing spread of coronavirus variants, of which omicron is now the most predominant in the United States. The issue is that there's no unified global approach as to how best to curtail omicron. Whereas some countries are now mandating vaccines, others are imposing few restrictions, if any.</p>\n<p>With a wide variance of mitigation measures being deployed, the single greatest risk to Wall Street is continued or brand-new supply chain issues. From tech and consumer goods to industrial companies, most sectors are at risk of operating shortfalls if global logistics continue to be tied into knots by the pandemic.</p>\n<h2>2. QE winding down</h2>\n<p>Another fairly obvious high-risk factor for Wall Street is the Federal Reserve going on the offensive against inflation. As a reminder, the Consumer Price Index for all Urban Consumers (CPI-U) rose 6.8% in November, which marked a 39-year high for inflation.</p>\n<p>Earlier this month, Federal Reserve Chairman Jerome Powell announced that the nation's central bank would expedite the winding down of its quantitative easing (QE) program. QE is the umbrella program responsible for buying long-term Treasury bonds (buying T-bonds pushes up their price and weighs down long-term yields) and mortgage-backed securities.</p>\n<p>Reduced bond buying should equate to higher borrowing rates, which in turn can slow the growth potential of previously fast-paced stocks.</p>\n<h2>3. Margin calls</h2>\n<p>Wall Street should also be deeply concerned about rapidly rising levels of margin debt, which is the amount of money that's been borrowed by institutions or investors <i>with interest</i> to purchase or short-sell securities.</p>\n<p>Over time, it's perfectly normal for the nominal amount of outstanding margin debt to climb. But since the March 2020 low, the amount of outstanding margin debt has come close to doubling, and now sits at nearly $919 billion, according to November data from the independent Financial Industry Regulatory Authority.</p>\n<p>There have only been three instances in the last 26 years where margin debt outstanding rose by at least 60% in a single year. It happened just months before the dot-com bubble burst, almost immediately ahead of the financial crisis, and in 2021. If stocks drift lower to begin the year, a margin-call wave could really accelerate things to the downside.</p>\n<h2>4. Sector rotation</h2>\n<p>Sometimes, the stock market dives for purely benign reasons. One such possibility is if we witness sector rotation in January. Sector rotation refers to investors moving money from one sector of the market to another.</p>\n<p>On the surface, you'd think a broad-based index like the S&amp;P 500 wouldn't be fazed by sector rotation. But it's no secret that growth stocks in the technology and healthcare sectors have been primarily leading this rally from the March 2020 bear market bottom. Now that we're well past the one-year mark since this bottom, it wouldn't be all that surprising to see investors locking in some profits on companies with valuation premiums and migrating some of their cash to safer/value investments or dividend plays.</p>\n<p>If investors do begin to choose value and dividends over growth stocks, there's little question the market-cap-weighted S&amp;P 500 will find itself under pressure.</p>\n<h2>5. Meme stock reversion</h2>\n<p>A fifth reason the stock market could crash in January is the potential for a dive in meme stocks, such as <b>AMC Entertainment Holdings</b>&nbsp;and <b>GameStop</b>.</p>\n<p>Even though these are grossly overvalued companies that have become detached from their respectively poor operating performances, the Fed noted in its semiannual Financial Stability Report that near- and long-term risks exist with the way young and novice investors have been putting their money to work.</p>\n<p>In particular, the report highlights that households invested in these social-media-driven stocks tend to have more-leveraged balance sheets. If common sense prevails and these bubble-like stocks begin to deflate, these leveraged investors may have no choice but to retreat, leading to increased market volatility.</p>\n<h2>6. Valuation</h2>\n<p>Even though valuation is rarely ever enough, by itself, to send the S&amp;P 500 screaming lower, historic precedents do suggest Wall Street may be in trouble come January.</p>\n<p>As of the closing bell on Dec. 21, the S&amp;P 500's Shiller price-to-earnings (P/E) ratio was 39. The Shiller P/E takes into account inflation-adjusted earnings over the past 10 years. Though the Shiller P/E multiple for the S&amp;P 500 has risen a bit since the advent of the internet in the mid-1990s, the current Shiller P/E is more than double its 151-year average of 16.9.</p>\n<p>What's far more worrisome is that the S&amp;P 500 has declined at least 20% in each of the previous four instances when the Shiller P/E surpassed 30. Wall Street simply doesn't have a good track record of supporting extreme valuations for long periods of time.</p>\n<h2>7. History makes its presence felt</h2>\n<p>Lastly, investors can look to history as another reason to be concerned about the broader market.</p>\n<p>Since 1960, there have been nine bear market declines (20% or more) for the S&amp;P 500. Following each of the previous eight bear market bottoms (i.e., not including the coronavirus crash), the S&amp;P 500 underwent either one or two double-digit percentage declines in the subsequent 36 months. We're now 21 months removed from the March 2020 bear market low and haven't come close to a double-digit correction in the broad-market index.</p>\n<p>Keep in mind that if a stock market crash or correction does occur in January, it would represent a fantastic buying opportunity for long-term investors. Just be aware that crashes and corrections are the price of admission to one of the world's greatest wealth creators.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Reasons the Stock Market Could Crash in January</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Reasons the Stock Market Could Crash in January\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-26 08:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/25/7-reasons-the-stock-market-could-crash-in-january/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In less than a week, we'll officially be ringing in a new year. However, Wall Street might be sad to see 2021 come to a close. The benchmark S&P 500 (SNPINDEX:^GSPC) has more than doubled up (+24%) ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/25/7-reasons-the-stock-market-could-crash-in-january/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","UPRO":"三倍做多标普500ETF","SDS":"两倍做空标普500ETF","SH":"标普500反向ETF","OEX":"标普100",".SPX":"S&P 500 Index","SPY":"标普500ETF","BK4559":"巴菲特持仓","SSO":"两倍做多标普500ETF","BK4534":"瑞士信贷持仓","IVV":"标普500指数ETF","OEF":"标普100指数ETF-iShares","BK4550":"红杉资本持仓","SPXU":"三倍做空标普500ETF","BK4504":"桥水持仓"},"source_url":"https://www.fool.com/investing/2021/12/25/7-reasons-the-stock-market-could-crash-in-january/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2194711211","content_text":"In less than a week, we'll officially be ringing in a new year. However, Wall Street might be sad to see 2021 come to a close. The benchmark S&P 500 (SNPINDEX:^GSPC) has more than doubled up (+24%) its average annual total return of 11% (including dividends) over the past four decades, and it hasn't undergone a steeper correction than 5%. It's been a true running of the bulls.\nBut as we turn the page on 2021, it's quite possible Wall Street could lose its luster. Below are seven reasons the stock market could crash in January.\n1. Omicron supply chain issues (domestic and abroad)\nThe most obvious obstacle for the S&P 500 is the ongoing spread of coronavirus variants, of which omicron is now the most predominant in the United States. The issue is that there's no unified global approach as to how best to curtail omicron. Whereas some countries are now mandating vaccines, others are imposing few restrictions, if any.\nWith a wide variance of mitigation measures being deployed, the single greatest risk to Wall Street is continued or brand-new supply chain issues. From tech and consumer goods to industrial companies, most sectors are at risk of operating shortfalls if global logistics continue to be tied into knots by the pandemic.\n2. QE winding down\nAnother fairly obvious high-risk factor for Wall Street is the Federal Reserve going on the offensive against inflation. As a reminder, the Consumer Price Index for all Urban Consumers (CPI-U) rose 6.8% in November, which marked a 39-year high for inflation.\nEarlier this month, Federal Reserve Chairman Jerome Powell announced that the nation's central bank would expedite the winding down of its quantitative easing (QE) program. QE is the umbrella program responsible for buying long-term Treasury bonds (buying T-bonds pushes up their price and weighs down long-term yields) and mortgage-backed securities.\nReduced bond buying should equate to higher borrowing rates, which in turn can slow the growth potential of previously fast-paced stocks.\n3. Margin calls\nWall Street should also be deeply concerned about rapidly rising levels of margin debt, which is the amount of money that's been borrowed by institutions or investors with interest to purchase or short-sell securities.\nOver time, it's perfectly normal for the nominal amount of outstanding margin debt to climb. But since the March 2020 low, the amount of outstanding margin debt has come close to doubling, and now sits at nearly $919 billion, according to November data from the independent Financial Industry Regulatory Authority.\nThere have only been three instances in the last 26 years where margin debt outstanding rose by at least 60% in a single year. It happened just months before the dot-com bubble burst, almost immediately ahead of the financial crisis, and in 2021. If stocks drift lower to begin the year, a margin-call wave could really accelerate things to the downside.\n4. Sector rotation\nSometimes, the stock market dives for purely benign reasons. One such possibility is if we witness sector rotation in January. Sector rotation refers to investors moving money from one sector of the market to another.\nOn the surface, you'd think a broad-based index like the S&P 500 wouldn't be fazed by sector rotation. But it's no secret that growth stocks in the technology and healthcare sectors have been primarily leading this rally from the March 2020 bear market bottom. Now that we're well past the one-year mark since this bottom, it wouldn't be all that surprising to see investors locking in some profits on companies with valuation premiums and migrating some of their cash to safer/value investments or dividend plays.\nIf investors do begin to choose value and dividends over growth stocks, there's little question the market-cap-weighted S&P 500 will find itself under pressure.\n5. Meme stock reversion\nA fifth reason the stock market could crash in January is the potential for a dive in meme stocks, such as AMC Entertainment Holdings and GameStop.\nEven though these are grossly overvalued companies that have become detached from their respectively poor operating performances, the Fed noted in its semiannual Financial Stability Report that near- and long-term risks exist with the way young and novice investors have been putting their money to work.\nIn particular, the report highlights that households invested in these social-media-driven stocks tend to have more-leveraged balance sheets. If common sense prevails and these bubble-like stocks begin to deflate, these leveraged investors may have no choice but to retreat, leading to increased market volatility.\n6. Valuation\nEven though valuation is rarely ever enough, by itself, to send the S&P 500 screaming lower, historic precedents do suggest Wall Street may be in trouble come January.\nAs of the closing bell on Dec. 21, the S&P 500's Shiller price-to-earnings (P/E) ratio was 39. The Shiller P/E takes into account inflation-adjusted earnings over the past 10 years. Though the Shiller P/E multiple for the S&P 500 has risen a bit since the advent of the internet in the mid-1990s, the current Shiller P/E is more than double its 151-year average of 16.9.\nWhat's far more worrisome is that the S&P 500 has declined at least 20% in each of the previous four instances when the Shiller P/E surpassed 30. Wall Street simply doesn't have a good track record of supporting extreme valuations for long periods of time.\n7. History makes its presence felt\nLastly, investors can look to history as another reason to be concerned about the broader market.\nSince 1960, there have been nine bear market declines (20% or more) for the S&P 500. Following each of the previous eight bear market bottoms (i.e., not including the coronavirus crash), the S&P 500 underwent either one or two double-digit percentage declines in the subsequent 36 months. We're now 21 months removed from the March 2020 bear market low and haven't come close to a double-digit correction in the broad-market index.\nKeep in mind that if a stock market crash or correction does occur in January, it would represent a fantastic buying opportunity for long-term investors. Just be aware that crashes and corrections are the price of admission to one of the world's greatest wealth creators.","news_type":1},"isVote":1,"tweetType":1,"viewCount":612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696136585,"gmtCreate":1640648278195,"gmtModify":1640648278195,"author":{"id":"4094037277039370","authorId":"4094037277039370","name":"214455ec","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"Thanks","listText":"Thanks","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696136585","repostId":"1127544468","repostType":4,"repost":{"id":"1127544468","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640646504,"share":"https://www.laohu8.com/m/news/1127544468?lang=&edition=full","pubTime":"2021-12-28 07:08","market":"us","language":"en","title":"S&P 500 closes at record high on retail sales cheer","url":"https://stock-news.laohu8.com/highlight/detail?id=1127544468","media":"Reuters","summary":"Dec 27  - The S&P 500 indexended at a record high on Monday, its fourth straight session of gains, as strong U.S. retail sales underscored economic strength and eased worries from Omicron-driven flight cancellations that hit travel stocks.U.S. retail sales increased 8.5% year-over-year this holiday season, powered by an ecommerce boom, according to a Mastercard Inc report, giving the S&P 500 retailing indexa boost.Travel-related stocks, typically sensitive to coronavirus news, declined after U.S","content":"<p>Dec 27 (Reuters) - The S&amp;P 500 index(.SPX)ended at a record high on Monday, its fourth straight session of gains, as strong U.S. retail sales underscored economic strength and eased worries from Omicron-driven flight cancellations that hit travel stocks.</p>\n<p>U.S. retail sales increased 8.5% year-over-year this holiday season, powered by an ecommerce boom, according to a Mastercard Inc report, giving the S&amp;P 500 retailing index(.SPXRT)a boost.</p>\n<p>Travel-related stocks, typically sensitive to coronavirus news, declined after U.S. airlines canceled about 800 more flights on Monday after nixing thousands during the Christmas weekend, as Omicron cases soared.</p>\n<p>The S&amp;P 1500 airlines index&nbsp;shed 0.57%. Cruise operators <a href=\"https://laohu8.com/S/NCLH\">Norwegian Cruise Line</a> Holdings, <a href=\"https://laohu8.com/S/RGLD\">Royal</a> Caribbean(RCL.N)and <a href=\"https://laohu8.com/S/CCL\">Carnival</a> Corp(CCL.N)fell 2.55%, 1.35% and 1.18% respectively, among the biggest decliners on the benchmark S&amp;P 500.</p>\n<p>\"The market is in this interesting place where we have a strong consumer, with spending up 8% year over year. Personal consumption makes up 70% of our GDP, and that remains flush,\" said Sylvia Jablonski Kampaktsis, chief investment officer and co-founder at Defiance ETFs in <a href=\"https://laohu8.com/S/NWY\">New York</a>.</p>\n<p>\"Omicron reminds us that we still exist in this corona ecosystem. And it'll probably be <a href=\"https://laohu8.com/S/AONE.U\">one</a> of many things that we will continue talking about with this virus but the doomsday COVID scenario of 2020 feels like it's far behind us.\"</p>\n<p>All 11 main S&amp;P 500 sector indexes advanced, with energy(.SPNY)and tech(.SPLRCT)leading percentage gains.</p>\n<p>The Dow Jones Industrial Average(.DJI)rose 351.82 points, or 0.98%, to 36,302.38, the S&amp;P 500(.SPX)gained 65.4 points, or 1.38%, to 4,791.19 and the <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> Composite(.IXIC)added 217.89 points, or 1.39%, to 15,871.26.</p>\n<p>The S&amp;P 500 has climbed 4.9% during its recent run of gains, its biggest percentage gain over a four-day period since early November 2020.</p>\n<p>The Nasdaq Composite(.IXIC)got a boost from megacap companies, including Tesla Inc(TSLA.O), <a href=\"https://laohu8.com/S/MSFT\">Microsoft</a> Corp(MSFT.O), <a href=\"https://laohu8.com/S/AAPL\">Apple</a> Inc(AAPL.O)and <a href=\"https://laohu8.com/S/CASH\">Meta</a> Platform(FB.O).</p>\n<p>Main U.S. stock indexes are on track for a third straight yearly gain, with the benchmark S&amp;P 500(.SPX)poised for its best three-year performance since 1999.</p>\n<p>Volume on U.S. exchanges was 7.76 billion shares, compared with the 11.74 billion average for the full session over the last 20 trading days.</p>\n<p>Advancing issues outnumbered decliners on the NYSE by a 2.29-to-1 ratio; on Nasdaq, a 1.09-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 58 new 52-week highs and no new lows; the Nasdaq Composite recorded 101 new highs and 145 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500 closes at record high on retail sales cheer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500 closes at record high on retail sales cheer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-28 07:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 27 (Reuters) - The S&amp;P 500 index(.SPX)ended at a record high on Monday, its fourth straight session of gains, as strong U.S. retail sales underscored economic strength and eased worries from Omicron-driven flight cancellations that hit travel stocks.</p>\n<p>U.S. retail sales increased 8.5% year-over-year this holiday season, powered by an ecommerce boom, according to a Mastercard Inc report, giving the S&amp;P 500 retailing index(.SPXRT)a boost.</p>\n<p>Travel-related stocks, typically sensitive to coronavirus news, declined after U.S. airlines canceled about 800 more flights on Monday after nixing thousands during the Christmas weekend, as Omicron cases soared.</p>\n<p>The S&amp;P 1500 airlines index&nbsp;shed 0.57%. Cruise operators <a href=\"https://laohu8.com/S/NCLH\">Norwegian Cruise Line</a> Holdings, <a href=\"https://laohu8.com/S/RGLD\">Royal</a> Caribbean(RCL.N)and <a href=\"https://laohu8.com/S/CCL\">Carnival</a> Corp(CCL.N)fell 2.55%, 1.35% and 1.18% respectively, among the biggest decliners on the benchmark S&amp;P 500.</p>\n<p>\"The market is in this interesting place where we have a strong consumer, with spending up 8% year over year. Personal consumption makes up 70% of our GDP, and that remains flush,\" said Sylvia Jablonski Kampaktsis, chief investment officer and co-founder at Defiance ETFs in <a href=\"https://laohu8.com/S/NWY\">New York</a>.</p>\n<p>\"Omicron reminds us that we still exist in this corona ecosystem. And it'll probably be <a href=\"https://laohu8.com/S/AONE.U\">one</a> of many things that we will continue talking about with this virus but the doomsday COVID scenario of 2020 feels like it's far behind us.\"</p>\n<p>All 11 main S&amp;P 500 sector indexes advanced, with energy(.SPNY)and tech(.SPLRCT)leading percentage gains.</p>\n<p>The Dow Jones Industrial Average(.DJI)rose 351.82 points, or 0.98%, to 36,302.38, the S&amp;P 500(.SPX)gained 65.4 points, or 1.38%, to 4,791.19 and the <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> Composite(.IXIC)added 217.89 points, or 1.39%, to 15,871.26.</p>\n<p>The S&amp;P 500 has climbed 4.9% during its recent run of gains, its biggest percentage gain over a four-day period since early November 2020.</p>\n<p>The Nasdaq Composite(.IXIC)got a boost from megacap companies, including Tesla Inc(TSLA.O), <a href=\"https://laohu8.com/S/MSFT\">Microsoft</a> Corp(MSFT.O), <a href=\"https://laohu8.com/S/AAPL\">Apple</a> Inc(AAPL.O)and <a href=\"https://laohu8.com/S/CASH\">Meta</a> Platform(FB.O).</p>\n<p>Main U.S. stock indexes are on track for a third straight yearly gain, with the benchmark S&amp;P 500(.SPX)poised for its best three-year performance since 1999.</p>\n<p>Volume on U.S. exchanges was 7.76 billion shares, compared with the 11.74 billion average for the full session over the last 20 trading days.</p>\n<p>Advancing issues outnumbered decliners on the NYSE by a 2.29-to-1 ratio; on Nasdaq, a 1.09-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 58 new 52-week highs and no new lows; the Nasdaq Composite recorded 101 new highs and 145 new lows.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","SPXU":"三倍做空标普500ETF","BK4550":"红杉资本持仓","BK4559":"巴菲特持仓","BK4504":"桥水持仓","BK4534":"瑞士信贷持仓","SSO":"两倍做多标普500ETF","OEX":"标普100",".SPX":"S&P 500 Index","SDS":"两倍做空标普500ETF","UPRO":"三倍做多标普500ETF","SH":"标普500反向ETF","OEF":"标普100指数ETF-iShares","SPY":"标普500ETF","IVV":"标普500指数ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127544468","content_text":"Dec 27 (Reuters) - The S&P 500 index(.SPX)ended at a record high on Monday, its fourth straight session of gains, as strong U.S. retail sales underscored economic strength and eased worries from Omicron-driven flight cancellations that hit travel stocks.\nU.S. retail sales increased 8.5% year-over-year this holiday season, powered by an ecommerce boom, according to a Mastercard Inc report, giving the S&P 500 retailing index(.SPXRT)a boost.\nTravel-related stocks, typically sensitive to coronavirus news, declined after U.S. airlines canceled about 800 more flights on Monday after nixing thousands during the Christmas weekend, as Omicron cases soared.\nThe S&P 1500 airlines index shed 0.57%. Cruise operators Norwegian Cruise Line Holdings, Royal Caribbean(RCL.N)and Carnival Corp(CCL.N)fell 2.55%, 1.35% and 1.18% respectively, among the biggest decliners on the benchmark S&P 500.\n\"The market is in this interesting place where we have a strong consumer, with spending up 8% year over year. Personal consumption makes up 70% of our GDP, and that remains flush,\" said Sylvia Jablonski Kampaktsis, chief investment officer and co-founder at Defiance ETFs in New York.\n\"Omicron reminds us that we still exist in this corona ecosystem. And it'll probably be one of many things that we will continue talking about with this virus but the doomsday COVID scenario of 2020 feels like it's far behind us.\"\nAll 11 main S&P 500 sector indexes advanced, with energy(.SPNY)and tech(.SPLRCT)leading percentage gains.\nThe Dow Jones Industrial Average(.DJI)rose 351.82 points, or 0.98%, to 36,302.38, the S&P 500(.SPX)gained 65.4 points, or 1.38%, to 4,791.19 and the Nasdaq Composite(.IXIC)added 217.89 points, or 1.39%, to 15,871.26.\nThe S&P 500 has climbed 4.9% during its recent run of gains, its biggest percentage gain over a four-day period since early November 2020.\nThe Nasdaq Composite(.IXIC)got a boost from megacap companies, including Tesla Inc(TSLA.O), Microsoft Corp(MSFT.O), Apple Inc(AAPL.O)and Meta Platform(FB.O).\nMain U.S. stock indexes are on track for a third straight yearly gain, with the benchmark S&P 500(.SPX)poised for its best three-year performance since 1999.\nVolume on U.S. exchanges was 7.76 billion shares, compared with the 11.74 billion average for the full session over the last 20 trading days.\nAdvancing issues outnumbered decliners on the NYSE by a 2.29-to-1 ratio; on Nasdaq, a 1.09-to-1 ratio favored advancers.\nThe S&P 500 posted 58 new 52-week highs and no new lows; the Nasdaq Composite recorded 101 new highs and 145 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":473,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692909153,"gmtCreate":1640819766981,"gmtModify":1640819766981,"author":{"id":"4094037277039370","authorId":"4094037277039370","name":"214455ec","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"Good to know","listText":"Good to know","text":"Good to know","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/692909153","repostId":"2195345230","repostType":4,"isVote":1,"tweetType":1,"viewCount":422,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691597279,"gmtCreate":1640218842725,"gmtModify":1640218842725,"author":{"id":"4094037277039370","authorId":"4094037277039370","name":"214455ec","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"This will be interesting since she's fighting the dominant power of Big Tech","listText":"This will be interesting since she's fighting the dominant power of Big Tech","text":"This will be interesting since she's fighting the dominant power of Big Tech","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/691597279","repostId":"2193186771","repostType":4,"repost":{"id":"2193186771","pubTimestamp":1640216899,"share":"https://www.laohu8.com/m/news/2193186771?lang=&edition=full","pubTime":"2021-12-23 07:48","market":"us","language":"en","title":"Amazon Cloud Unit Draws Antitrust Scrutiny From Khan’s FTC","url":"https://stock-news.laohu8.com/highlight/detail?id=2193186771","media":"Bloomberg","summary":"Federal investigators have contacted companies about AWS unit\nOutreach shows probe is active under F","content":"<ul>\n <li>Federal investigators have contacted companies about AWS unit</li>\n <li>Outreach shows probe is active under FTC’s new leadership</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fcf43101a091c05e4187d5ec226b2df3\" tg-width=\"3000\" tg-height=\"2001\" width=\"100%\" height=\"auto\"><span>Lina KhanPhotographer: Graeme Jennings/Washington Examiner/Bloomberg</span></p>\n<p>The U.S. Federal Trade Commission is pushing forward with antitrust scrutiny of&nbsp;Amazon.com Inc.’s cloud computing business, according to people familiar with the matter.</p>\n<p>Lina Khan, the head of the agency and a vocal critic of the online retailer, is advancing a probe started several years ago by her predecessor.</p>\n<p>FTC investigators have contacted companies in the past few months to gather information about competition issues related to Amazon Web Services, said the people, who declined to be named because they weren’t authorized to speak publicly about the outreach. At least one of the contacts was as recent as the past few weeks, said one of the people.</p>\n<p>The focus on Amazon’s $16 billion cloud business, which brings in most of the e-commerce giant’s profit, comes as Khan has set her sights on conduct by the biggest U.S. tech companies. Khan, a former Columbia Law School professor, rose to prominence in antitrust circles warning about the threats companies like Amazon pose to competition in the digital economy.</p>\n<p>Amazon fell almost 1% to $3,381 in New York after Bloomberg reported the news before closing higher at $3,420.74.</p>\n<p>One issue the FTC could look at is whether Amazon has an incentive to discriminate against software companies that sell their products to clients of AWS, while at the same time competing with Amazon. The fear is that Amazon could punish the companies that work with other cloud providers and favor those that it works with exclusively.</p>\n<p>The FTC’s investigation of Amazon began during the Trump administration under former chairman Joe Simons. The agency has pursued inquiries about Amazon’s&nbsp;retail business&nbsp;as well as the&nbsp;cloud division, Bloomberg has reported. The renewed outreach to companies shows the probe is active.</p>\n<p>Amazon has provided information to the FTC in response to the agency’s requests, according to a person familiar with the matter.</p>\n<p>Amazon and the FTC didn’t respond to requests for comment.</p>\n<p>The company filed a petition with the agency in June&nbsp;seeking Khan’s recusal&nbsp;from antitrust enforcement decisions against Amazon. The company argues that her past criticism of the company shows she is biased.</p>\n<p>AWS dominates the market for foundational cloud-computing technology that provides the storage and computing power needed to run applications. Amazon held 41% of the cloud-computing market in 2020, followed by&nbsp;Microsoft Corp.’s Azure at 20%, according to an&nbsp;estimate&nbsp;by research firm Gartner.</p>\n<p>Amazon also sells an array of products that run on top of those basic services, such as databases, machine-learning tools and data-warehousing products. It competes with hundreds of other software companies large and small that offer similar products.</p>\n<p>Cloud computing companies like Amazon, Microsoft and&nbsp;Oracle Corp.are vying for lucrative&nbsp;government contracts&nbsp;to provide cloud services to agencies including the Defense Department and the National Security Agency.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon Cloud Unit Draws Antitrust Scrutiny From Khan’s FTC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon Cloud Unit Draws Antitrust Scrutiny From Khan’s FTC\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 07:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-12-22/amazon-cloud-unit-draws-fresh-antitrust-scrutiny-from-khan-s-ftc><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Federal investigators have contacted companies about AWS unit\nOutreach shows probe is active under FTC’s new leadership\n\nLina KhanPhotographer: Graeme Jennings/Washington Examiner/Bloomberg\nThe U.S. ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-22/amazon-cloud-unit-draws-fresh-antitrust-scrutiny-from-khan-s-ftc\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4122":"互联网与直销零售","BK4503":"景林资产持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4524":"宅经济概念","BK4535":"淡马锡持仓","BK4561":"索罗斯持仓","BK4534":"瑞士信贷持仓","BK4559":"巴菲特持仓","BK4507":"流媒体概念","BK4538":"云计算","BK4527":"明星科技股","AMZN":"亚马逊","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BK4554":"元宇宙及AR概念"},"source_url":"https://www.bloomberg.com/news/articles/2021-12-22/amazon-cloud-unit-draws-fresh-antitrust-scrutiny-from-khan-s-ftc","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193186771","content_text":"Federal investigators have contacted companies about AWS unit\nOutreach shows probe is active under FTC’s new leadership\n\nLina KhanPhotographer: Graeme Jennings/Washington Examiner/Bloomberg\nThe U.S. Federal Trade Commission is pushing forward with antitrust scrutiny of Amazon.com Inc.’s cloud computing business, according to people familiar with the matter.\nLina Khan, the head of the agency and a vocal critic of the online retailer, is advancing a probe started several years ago by her predecessor.\nFTC investigators have contacted companies in the past few months to gather information about competition issues related to Amazon Web Services, said the people, who declined to be named because they weren’t authorized to speak publicly about the outreach. At least one of the contacts was as recent as the past few weeks, said one of the people.\nThe focus on Amazon’s $16 billion cloud business, which brings in most of the e-commerce giant’s profit, comes as Khan has set her sights on conduct by the biggest U.S. tech companies. Khan, a former Columbia Law School professor, rose to prominence in antitrust circles warning about the threats companies like Amazon pose to competition in the digital economy.\nAmazon fell almost 1% to $3,381 in New York after Bloomberg reported the news before closing higher at $3,420.74.\nOne issue the FTC could look at is whether Amazon has an incentive to discriminate against software companies that sell their products to clients of AWS, while at the same time competing with Amazon. The fear is that Amazon could punish the companies that work with other cloud providers and favor those that it works with exclusively.\nThe FTC’s investigation of Amazon began during the Trump administration under former chairman Joe Simons. The agency has pursued inquiries about Amazon’s retail business as well as the cloud division, Bloomberg has reported. The renewed outreach to companies shows the probe is active.\nAmazon has provided information to the FTC in response to the agency’s requests, according to a person familiar with the matter.\nAmazon and the FTC didn’t respond to requests for comment.\nThe company filed a petition with the agency in June seeking Khan’s recusal from antitrust enforcement decisions against Amazon. The company argues that her past criticism of the company shows she is biased.\nAWS dominates the market for foundational cloud-computing technology that provides the storage and computing power needed to run applications. Amazon held 41% of the cloud-computing market in 2020, followed by Microsoft Corp.’s Azure at 20%, according to an estimate by research firm Gartner.\nAmazon also sells an array of products that run on top of those basic services, such as databases, machine-learning tools and data-warehousing products. It competes with hundreds of other software companies large and small that offer similar products.\nCloud computing companies like Amazon, Microsoft and Oracle Corp.are vying for lucrative government contracts to provide cloud services to agencies including the Defense Department and the National Security Agency.","news_type":1},"isVote":1,"tweetType":1,"viewCount":469,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698371756,"gmtCreate":1640311503014,"gmtModify":1640313145337,"author":{"id":"4094037277039370","authorId":"4094037277039370","name":"214455ec","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"It's going to be another bumper year for Pfizer","listText":"It's going to be another bumper year for Pfizer","text":"It's going to be another bumper year for Pfizer","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698371756","repostId":"1110395878","repostType":4,"repost":{"id":"1110395878","pubTimestamp":1640310818,"share":"https://www.laohu8.com/m/news/1110395878?lang=&edition=full","pubTime":"2021-12-24 09:53","market":"us","language":"en","title":"Pfizer’s Covid Pill Gets Green Light. Investors Are Starting to Pay Attention to the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1110395878","media":"Barrons","summary":"The Covid-19 pill is here, and it couldn’t have come at a better time.\nThe pandemic grew darker over","content":"<p>The Covid-19 pill is here, and it couldn’t have come at a better time.</p>\n<p>The pandemic grew darker over the past two weeks, as the Omicron variant swept into the U.S. With most of the widely used therapies rendered useless by the variant’s mutations, and case counts quickly climbing, doctors and public health officials have been increasingly worried.</p>\n<p>The Food and Drug Administration’s authorization of&nbsp;Pfizer’s&nbsp;(ticker: PFE) Covid-19 pill Paxlovid on Wednesday offered some hope. The pill is cleared only for high-risk individuals, and supplies will initially be limited, but it will save lives.</p>\n<p>The authorization represents an extraordinary coup for Pfizer, its second of the pandemic. Analysts expect Pfizer to sell $21.7 billion worth of the drug in 2022, according to FactSet, though the company now says that it will make 120 million courses of the drug next year, 40 million more than previously forecast, which will probably drive those estimates higher.</p>\n<p>As <i>Barron’s</i> argued in November, the success of Paxlovid is more evidence that the company’s decision in 2019 to rid itself of all but its innovative biopharma business was a smart one.</p>\n<p>Investors had been slow to buy into the revamped Pfizer, but late this year they caught up fast. In the 12 months before November of this year, Pfizer shares trailed the&nbsp;S&amp;P 500&nbsp;index, even as it rolled out its Covid-19 vaccine. Since the start of November, however, Pfizer shares have exploded. The stock is up 36.4% since then, while the S&amp;P 500 has climbed just 1.6%.</p>\n<p>And the stock remains relatively cheap, trading at just 9.8 times earnings expected over the next 12 months, according to FactSet, a discount to peers like&nbsp;Eli Lilly&nbsp;(LLY), which trades at 31.7 times earnings, and&nbsp;Johnson &amp; Johnson&nbsp;(JNJ), at 16.1 times earnings.</p>\n<p>The good news for Pfizer this week was matched by less-good news for&nbsp;Merck&nbsp;(MRK). Though early data on its Covid-19 pill molnupiravir sent vaccine stocks lower and Merck shares higher, the shine has since come off the drug, as updated data have suggested that it’s less efficacious than it initially appeared, and safety questions have lingered.</p>\n<p>The FDA issued an emergency-use authorization for molnupiravir on Thursday, a day after it issued Paxlovid’s, under far more restrictive terms. The authorization allows for molnupiravir to be used only when other Covid-19 treatments, like Paxlovid, are not accessible or not clinically appropriate. The agency also did not recommend the drug for use during pregnancy, and advised that men who take molnupiravir should use birth control for at least three months afterward.</p>\n<p>Earlier hopes that molnupiravir could be a long-term revenue driver are evaporating. The disappointment is a reminder of the challenge facing Merck before the end of this decade: the loss of patent protections on Keytruda, the cancer drug blockbuster that accounts for roughly a third of its revenue. Merck has been working toward filling that gap. It doesn’t appear that molnupiravir will be a big contributor to that effort.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer’s Covid Pill Gets Green Light. Investors Are Starting to Pay Attention to the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer’s Covid Pill Gets Green Light. Investors Are Starting to Pay Attention to the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 09:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/pfizer-covid-pill-pfe-stock-51640266734?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Covid-19 pill is here, and it couldn’t have come at a better time.\nThe pandemic grew darker over the past two weeks, as the Omicron variant swept into the U.S. With most of the widely used ...</p>\n\n<a href=\"https://www.barrons.com/articles/pfizer-covid-pill-pfe-stock-51640266734?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/pfizer-covid-pill-pfe-stock-51640266734?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1110395878","content_text":"The Covid-19 pill is here, and it couldn’t have come at a better time.\nThe pandemic grew darker over the past two weeks, as the Omicron variant swept into the U.S. With most of the widely used therapies rendered useless by the variant’s mutations, and case counts quickly climbing, doctors and public health officials have been increasingly worried.\nThe Food and Drug Administration’s authorization of Pfizer’s (ticker: PFE) Covid-19 pill Paxlovid on Wednesday offered some hope. The pill is cleared only for high-risk individuals, and supplies will initially be limited, but it will save lives.\nThe authorization represents an extraordinary coup for Pfizer, its second of the pandemic. Analysts expect Pfizer to sell $21.7 billion worth of the drug in 2022, according to FactSet, though the company now says that it will make 120 million courses of the drug next year, 40 million more than previously forecast, which will probably drive those estimates higher.\nAs Barron’s argued in November, the success of Paxlovid is more evidence that the company’s decision in 2019 to rid itself of all but its innovative biopharma business was a smart one.\nInvestors had been slow to buy into the revamped Pfizer, but late this year they caught up fast. In the 12 months before November of this year, Pfizer shares trailed the S&P 500 index, even as it rolled out its Covid-19 vaccine. Since the start of November, however, Pfizer shares have exploded. The stock is up 36.4% since then, while the S&P 500 has climbed just 1.6%.\nAnd the stock remains relatively cheap, trading at just 9.8 times earnings expected over the next 12 months, according to FactSet, a discount to peers like Eli Lilly (LLY), which trades at 31.7 times earnings, and Johnson & Johnson (JNJ), at 16.1 times earnings.\nThe good news for Pfizer this week was matched by less-good news for Merck (MRK). Though early data on its Covid-19 pill molnupiravir sent vaccine stocks lower and Merck shares higher, the shine has since come off the drug, as updated data have suggested that it’s less efficacious than it initially appeared, and safety questions have lingered.\nThe FDA issued an emergency-use authorization for molnupiravir on Thursday, a day after it issued Paxlovid’s, under far more restrictive terms. The authorization allows for molnupiravir to be used only when other Covid-19 treatments, like Paxlovid, are not accessible or not clinically appropriate. The agency also did not recommend the drug for use during pregnancy, and advised that men who take molnupiravir should use birth control for at least three months afterward.\nEarlier hopes that molnupiravir could be a long-term revenue driver are evaporating. The disappointment is a reminder of the challenge facing Merck before the end of this decade: the loss of patent protections on Keytruda, the cancer drug blockbuster that accounts for roughly a third of its revenue. Merck has been working toward filling that gap. It doesn’t appear that molnupiravir will be a big contributor to that effort.","news_type":1},"isVote":1,"tweetType":1,"viewCount":387,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698728205,"gmtCreate":1640562084831,"gmtModify":1640562084831,"author":{"id":"4094037277039370","authorId":"4094037277039370","name":"214455ec","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"Thanks","listText":"Thanks","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698728205","repostId":"1132821017","repostType":4,"isVote":1,"tweetType":1,"viewCount":444,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698621483,"gmtCreate":1640388863343,"gmtModify":1640388863343,"author":{"id":"4094037277039370","authorId":"4094037277039370","name":"214455ec","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698621483","repostId":"1122704248","repostType":4,"repost":{"id":"1122704248","pubTimestamp":1640346833,"share":"https://www.laohu8.com/m/news/1122704248?lang=&edition=full","pubTime":"2021-12-24 19:53","market":"us","language":"en","title":"3 Charts to Consider if You Want to Own an EV Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1122704248","media":"Motley Fool","summary":"There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some","content":"<p>There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some stocks have been exceptional over the last two years. Now, the landscape for the sector seems to be clearing so investors can get a better idea of who the players are, and over what time frame EV makers will be bringing out new offerings.</p>\n<p>Beyond just looking at the exciting new products and potentially huge market,investors should research&nbsp;details that will help compare and contrast the EV makers. If you're interested in diving in now, the three charts below will provide a look at some data worth considering before you make an investment.</p>\n<p><b>Returns have been unpredictable</b></p>\n<p>Many have bought into the EV sector looking for large, market-beating returns. While shares of EV leader<b>Tesla</b>(NASDAQ:TSLA)skyrocketed last year, as the field of publicly traded names has grown, returns have been inconsistent. And investors need to be prepared for plenty of volatility along the way. The chart below shows the most recent six-month returns from a mix of U.S.- and China-based EV makers:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/628cf15ff39a9f1a896ba56a7db9020d\" tg-width=\"720\" tg-height=\"387\" width=\"100%\" height=\"auto\"><span>DATA BYYCHARTS.</span></p>\n<p>Even the strong returns from Tesla and&nbsp;<b>Lucid Group</b>(NASDAQ:LCID)stocks have included big swings in just the past two months. And though Chinese EV makers&nbsp;<b>Nio</b>(NYSE:NIO)&nbsp;and&nbsp;<b>XPeng</b>(NYSE:XPEV)have been growing sales quickly, their stocks have backtracked since June 2021.<b>Lordstown Motors</b>(NASDAQ:RIDE), maker of the Endurance all-electric work truck, has struggled, and shareholders have paid the price this year. The lesson is that there will be winners and losers, and EV stock moves can be quick and extreme.</p>\n<p><b>There's plenty of demand</b></p>\n<p>Just looking at share-price movement doesn't tell the full story, of course. While Nio and XPeng shares haven't moved higher in the last half-year, both company's sales skyrocketed over the first nine months of 2021, as shown below:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7a2201193c16f33bc21f52f5aacebbea\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>DATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.*XPENG 2021 COMPARISON WITH FINAL THREE QUARTERS OF 2020.</span></p>\n<p>Tesla has almost doubled its deliveries over the first nine months of 2021 compared to the year-ago period. But XPeng andNio deliveries are growing much faster, though the two Chinese companies are growing off of a much smaller base. And as both are already richly valued, with recent&nbsp;market capitalizations&nbsp;of around $36 billion and $48 billion, respectively, investors have sold off shares in recent months. Global demand is strong and growing, but that won't automatically result in growing share prices.</p>\n<p><b>Profitability will take time</b></p>\n<p>Investors in any business need to focus on the bottom line. Early stage growth companies aren't necessarily expected to become profitable quickly, however. Especially with a high-fixed-cost business like automotive manufacturing, profits will only come with scale. As the chart below shows, few EV makers are bringing in profits yet:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/32eab03a7b97ed8deb8757e127924d51\" tg-width=\"700\" tg-height=\"495\" width=\"100%\" height=\"auto\"><span>DATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.</span></p>\n<p>Tesla led the industry with a reported profit of more than $1.6 billion in the third quarter of 2021 .</p>\n<p>BYD is perhaps a less well-known Chinese EV company, and it sells more than just&nbsp;electric cars; it also makes batteries, electric buses, and traditional internal combustion vehicles. But its \"new energy vehicles\" -- which include plug-in hybrid electrics -- made up more than 90% of the nearly 100,000 new energy passenger vehicles it delivered in November.</p>\n<p>Lucid and&nbsp;<b>Rivian Automotive</b>(NASDAQ:RIVN)are getting a lot of attention recently, but they've barely started shipping product; the losses there will continue for some time until those companies reach scale. Investors hope that Nio and XPeng reach profitability soon, as both are growing sales and expanding product offerings. But investors interested in the sector need to be prepared for a long road before profitability can be expected.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Charts to Consider if You Want to Own an EV Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Charts to Consider if You Want to Own an EV Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 19:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/24/3-charts-to-consider-to-own-an-ev-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some stocks have been exceptional over the last two years. Now, the landscape for the sector seems to be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/3-charts-to-consider-to-own-an-ev-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","LCID":"Lucid Group Inc","TSLA":"特斯拉","XPEV":"小鹏汽车","RIVN":"Rivian Automotive, Inc."},"source_url":"https://www.fool.com/investing/2021/12/24/3-charts-to-consider-to-own-an-ev-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122704248","content_text":"There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some stocks have been exceptional over the last two years. Now, the landscape for the sector seems to be clearing so investors can get a better idea of who the players are, and over what time frame EV makers will be bringing out new offerings.\nBeyond just looking at the exciting new products and potentially huge market,investors should research details that will help compare and contrast the EV makers. If you're interested in diving in now, the three charts below will provide a look at some data worth considering before you make an investment.\nReturns have been unpredictable\nMany have bought into the EV sector looking for large, market-beating returns. While shares of EV leaderTesla(NASDAQ:TSLA)skyrocketed last year, as the field of publicly traded names has grown, returns have been inconsistent. And investors need to be prepared for plenty of volatility along the way. The chart below shows the most recent six-month returns from a mix of U.S.- and China-based EV makers:\nDATA BYYCHARTS.\nEven the strong returns from Tesla and Lucid Group(NASDAQ:LCID)stocks have included big swings in just the past two months. And though Chinese EV makers Nio(NYSE:NIO) and XPeng(NYSE:XPEV)have been growing sales quickly, their stocks have backtracked since June 2021.Lordstown Motors(NASDAQ:RIDE), maker of the Endurance all-electric work truck, has struggled, and shareholders have paid the price this year. The lesson is that there will be winners and losers, and EV stock moves can be quick and extreme.\nThere's plenty of demand\nJust looking at share-price movement doesn't tell the full story, of course. While Nio and XPeng shares haven't moved higher in the last half-year, both company's sales skyrocketed over the first nine months of 2021, as shown below:\nDATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.*XPENG 2021 COMPARISON WITH FINAL THREE QUARTERS OF 2020.\nTesla has almost doubled its deliveries over the first nine months of 2021 compared to the year-ago period. But XPeng andNio deliveries are growing much faster, though the two Chinese companies are growing off of a much smaller base. And as both are already richly valued, with recent market capitalizations of around $36 billion and $48 billion, respectively, investors have sold off shares in recent months. Global demand is strong and growing, but that won't automatically result in growing share prices.\nProfitability will take time\nInvestors in any business need to focus on the bottom line. Early stage growth companies aren't necessarily expected to become profitable quickly, however. Especially with a high-fixed-cost business like automotive manufacturing, profits will only come with scale. As the chart below shows, few EV makers are bringing in profits yet:\nDATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.\nTesla led the industry with a reported profit of more than $1.6 billion in the third quarter of 2021 .\nBYD is perhaps a less well-known Chinese EV company, and it sells more than just electric cars; it also makes batteries, electric buses, and traditional internal combustion vehicles. But its \"new energy vehicles\" -- which include plug-in hybrid electrics -- made up more than 90% of the nearly 100,000 new energy passenger vehicles it delivered in November.\nLucid and Rivian Automotive(NASDAQ:RIVN)are getting a lot of attention recently, but they've barely started shipping product; the losses there will continue for some time until those companies reach scale. Investors hope that Nio and XPeng reach profitability soon, as both are growing sales and expanding product offerings. But investors interested in the sector need to be prepared for a long road before profitability can be expected.","news_type":1},"isVote":1,"tweetType":1,"viewCount":497,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691530854,"gmtCreate":1640218928679,"gmtModify":1640218928679,"author":{"id":"4094037277039370","authorId":"4094037277039370","name":"214455ec","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0},"themes":[],"htmlText":"This will help the economy to avoid lock downs&nbsp;","listText":"This will help the economy to avoid lock downs&nbsp;","text":"This will help the economy to avoid lock downs","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691530854","repostId":"1131862374","repostType":4,"repost":{"id":"1131862374","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640213195,"share":"https://www.laohu8.com/m/news/1131862374?lang=&edition=full","pubTime":"2021-12-23 06:46","market":"us","language":"en","title":"U.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use","url":"https://stock-news.laohu8.com/highlight/detail?id=1131862374","media":"Reuters","summary":"Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's antiviral COVID-19 pill fo","content":"<p>Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's&nbsp;antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading&nbsp;Omicron variant.</p>\n<p>Pfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.</p>\n<p>Pfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.</p>\n<p>\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.</p>\n<p>\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.</p>\n<p>Pfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.</p>\n<p>The Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing&nbsp;plans for more federal&nbsp;vaccination and testing sites.</p>\n<p>The pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.</p>\n<p>Monoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.</p>\n<p>The Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.</p>\n<p>The FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.</p>\n<p>The drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA&nbsp;said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.</p>\n<p>While the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).</p>\n<p>The second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.</p>\n<p>Pfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.</p>\n<p>Pfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.</p>\n<p>A rival pill from Merck &amp; Co&nbsp;is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-23 06:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's&nbsp;antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading&nbsp;Omicron variant.</p>\n<p>Pfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.</p>\n<p>Pfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.</p>\n<p>\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.</p>\n<p>\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.</p>\n<p>Pfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.</p>\n<p>The Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing&nbsp;plans for more federal&nbsp;vaccination and testing sites.</p>\n<p>The pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.</p>\n<p>Monoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.</p>\n<p>The Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.</p>\n<p>The FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.</p>\n<p>The drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA&nbsp;said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.</p>\n<p>While the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).</p>\n<p>The second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.</p>\n<p>Pfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.</p>\n<p>Pfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.</p>\n<p>A rival pill from Merck &amp; Co&nbsp;is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131862374","content_text":"Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading Omicron variant.\nPfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.\nPfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.\n\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.\n\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.\nPfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.\nThe Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing plans for more federal vaccination and testing sites.\nThe pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.\nMonoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.\nThe Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.\nThe FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.\nThe drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.\nWhile the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).\nThe second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.\nPfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.\nPfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.\nA rival pill from Merck & Co is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.","news_type":1},"isVote":1,"tweetType":1,"viewCount":866,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}